Document:

<PAGE>

                                                                    EXHIBIT 4.3

================================================================================

                               SECURITY AGREEMENT

                                   dated as of

                                 July 24, 2003,

                                      among

                              AK STEEL CORPORATION,

                           CREDIT SUISSE FIRST BOSTON,
                    acting through its Cayman Islands branch,
                            as Administrative Agent,

                                       and

                      GENERAL ELECTRIC CAPITAL CORPORATION,
                               as Collateral Agent

================================================================================

                                                             SECURITY AGREEMENT

<PAGE>

                                TABLE OF CONTENTS
                                -----------------
                                                                            PAGE
                                                                            ----

SECTION 1.  DEFINITIONS AND RULES OF CONSTRUCTION..............................1

SECTION 2.  GRANT OF SECURITY INTERESTS........................................6

SECTION 3.  REPRESENTATIONS AND WARRANTIES.....................................8

SECTION 4.  COVENANTS.........................................................10

SECTION 5.  DEPOSIT ACCOUNTS..................................................12

SECTION 6.  REMEDIES..........................................................14

SECTION 7.  APPLICATION OF PAYMENTS...........................................18

SECTION 8.  TAXES, FEES AND EXPENSES..........................................19

SECTION 9.  POWER OF ATTORNEY.................................................20

SECTION 10. LIMITED DUTY......................................................21

SECTION 11. RIGHTS OF COLLATERAL AGENT........................................21

SECTION 12. RELEASE OF COLLATERAL.............................................23

SECTION 13. NOTICES...........................................................24

SECTION 14. NO IMPLIED WAIVER; REMEDIES CUMULATIVE............................24

SECTION 15. BENEFIT OF AGREEMENT..............................................24

SECTION 16. AMENDMENTS, CONSENTS AND WAIVERS..................................25

SECTION 17. GOVERNING LAW.....................................................25

SECTION 18. WAIVER OF JURY TRIAL..............................................25

SECTION 19. SEVERABILITY......................................................25

SECTION 20. REINSTATEMENT.....................................................25

SECTION 21. CONSENT TO JURISDICTION AND SERVICE OF PROCESS....................26

                                      -i-                     SECURITY AGREEMENT

<PAGE>

                               SECURITY AGREEMENT
                               ------------------

             SECURITY AGREEMENT dated as of July 24, 2003, among AK STEEL
CORPORATION (the "Grantor"), CREDIT SUISSE FIRST BOSTON, acting through its
Cayman Islands branch, as Administrative Agent, and GENERAL ELECTRIC CAPITAL
CORPORATION, as Collateral Agent.

                                   WITNESSETH:
                                   ----------

             WHEREAS, the Company has entered into the Credit Agreement
described in Section 1(c) hereof, pursuant to which the Company intends to
borrow funds and obtain letters of credit for the purposes set forth therein;

             WHEREAS, the Grantor is willing to secure its obligations under the
Loan Documents by granting Liens on certain of its assets to the Collateral
Agent as provided in the Collateral Documents;

             WHEREAS, the Lenders are willing to make loans and issue and
participate in Letters of Credit under the Credit Agreement upon the terms and
subject to the conditions set forth therein if the foregoing obligations of the
Grantor are secured as described above; and

             WHEREAS, upon any foreclosure or other enforcement of the
Collateral Documents, the net proceeds of the relevant Collateral are to be
received by or paid over to the Collateral Agent and applied as provided in
Section 7 hereof;

             NOW, THEREFORE, in consideration of the foregoing and of other good
and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

SECTION 1.   DEFINITIONS AND RULES OF CONSTRUCTION.

             (a)  Terms Defined in Credit Agreement. Terms defined in the Credit
Agreement and not otherwise defined in this Security Agreement have, as used
herein, the respective meanings provided for therein.

             (b)  Terms Defined in UCC. As used herein, each of the following
terms has the meaning specified in the below-referenced Section of the UCC (or
any successor provision):

             Term                                                   UCC
             ----                                                   ---

             Account........................................9-102(a)(2)

             Authenticate...................................9-102(a)(7)

             Chattel Paper.................................9-102(a)(11)

             Documents.....................................9-102(a)(30)

                                                              SECURITY AGREEMENT

<PAGE>

             General Intangibles...........................9-102(a)(42)

             Instrument....................................9-102(a)(47)

             Supporting Obligation.........................9-102(a)(77)

             (c)  Additional Definitions. The following additional terms, as
used herein, have the following meanings:

             "Administrative Agent" means Credit Suisse First Boston, acting
through its Cayman Islands branch, in its capacity as Administrative Agent
under the Loan Documents, and its successors in such capacity.

             "Aggregate Available Amount" has the meaning specified in Section
6(d).

             "Company" means AK Steel Corporation, a Delaware corporation, and
its successors.

             "Collateral" means all property, whether now owned or hereafter
acquired, on which a Lien is granted or purported to be granted to the
Collateral Agent pursuant to the Collateral Documents.

             "Collateral Account" means the restricted Deposit Account
established and maintained by the Collateral Agent pursuant to Section 5(a)
(ii).

             "Collateral Agent" means General Electric Capital Corporation, in
its capacity as Collateral Agent for the Secured Parties under the Collateral
Documents, and its successors in such capacity.

             "Collections" has the meaning ascribed to such term in the
Intercreditor Agreement.

             "Credit Agreement" means that certain Credit Agreement, dated as of
July 24, 2003, among the Company, the Lenders party thereto, Credit Suisse First
Boston, acting through its Cayman Islands branch, as Administrative Agent,
General Electric Capital Corporation, as Syndication Agent and Collateral Agent,
and The CIT Group / Business Credit, Inc., Bank One, NA, and Congress Financial
Corporation, as Co-Documentation Agents, as amended or restated from time to
time in accordance with the terms thereof.

             "Eligible Transferee" means the Existing Receivables SPV and any
other special-purpose company created and used solely for purposes of effecting
a Permitted Receivables Securitization Program.

             "Event of Default" means any Event of Default as defined in the
Credit Agreement.

             "Existing Receivables SPV Deposit Accounts" has the meaning
ascribed to such term in Section 5(b).

                                      -2-                     SECURITY AGREEMENT

<PAGE>

             "Grantor" has the meaning ascribed to such term in the preamble to
this Security Agreement.

             "Intangible Property" has the meaning specified in Section
2(a)(vi).

             "Inventory" means any "inventory," as such term is defined in the
UCC, now or hereafter owned or acquired by the Grantor wherever located, and, in
any event, including all inventory, merchandise, goods and other personal
property that are held by or on behalf of the Grantor for sale or lease or are
furnished or are to be furnished under a contract of service or that constitute
raw materials, work in process, or materials used or consumed or to be used or
consumed in the business of Holdings or any of its Subsidiaries or in the
processing, packaging, advertising, promotion, delivery or shipping of the same,
and all finished goods and all proceeds and products thereof.

             "Liquidated Secured Obligation" means at any time any Secured
Obligation (or portion thereof) that is not an Unliquidated Secured Obligation
at such time.

             "Maximum Available Amount" has the meaning specified in Section
6(d).

             "Opinion of Counsel" means a written opinion of legal counsel (who
may be counsel to the Grantor or other counsel, in either case approved by the
Administrative Agent and the Collateral Agent in writing, which approval shall
not be unreasonably withheld) addressed and delivered to the Administrative
Agent and the Collateral Agent.

             "own" refers to the possession of sufficient rights in property to
grant a security interest therein as contemplated by UCC Section 9-203 (or any
successor provision), and "acquire" refers to the acquisition of any such
rights.

             "Perfection Certificate" means a certificate from the Grantor
substantially in the form of Annex A to this Security Agreement, completed and
supplemented with the schedules contemplated thereby to the reasonable
satisfaction of the Collateral Agent, and signed by an officer of the Grantor.

             "Permitted Liens" means (i) the Transaction Liens and (ii) any
other Liens permitted to be created or assumed or to exist pursuant to the
Credit Agreement, including Liens arising in connection with Permitted
Receivables Securitization Programs (including the Existing Receivables
Securitization Program).

             "Pledged", when used in conjunction with any type of asset, means
at any time an asset of such type that is included (or that creates rights that
are included) in the Collateral at such time. For example, "Pledged Inventory"
means Inventory that is included in the Collateral at such time.

             "Proceeds" means any "proceeds" as such term is defined in the UCC,
and, in any event, including all proceeds of, and all other profits, products,
rents or receipts, in whatever form, arising from the collection, sale, lease,
exchange, assignment, licensing or other disposition of, or other realization
upon, any Collateral, including all claims of the Grantor against third parties
for loss of, damage to or destruction of, or for proceeds payable under, or
unearned

                                      -3-                     SECURITY AGREEMENT

<PAGE>

premiums with respect to, policies of insurance in respect of, any Collateral,
and any condemnation or requisition payments with respect to any Collateral.

             "Purchased Receivables" has the meaning ascribed to such term in
the Intercreditor Agreement.

             "Purchased Receivables Collection Account" means each "Collection
Account" as defined in the Existing Purchase and Servicing Agreement.

             "Purchased Receivables Concentration Account" means the
"Concentration Account" as defined in the Purchase and Servicing Agreement.

             "Purchaser Agent" has the meaning ascribed to such term in the
Intercreditor Agreement.

             "Receivables" means all Accounts owned by the Grantor and all other
rights, titles or interests that, in accordance with GAAP, would be included in
receivables on its balance sheet (including any such Accounts and/or rights,
titles or interests that might be characterized as Chattel Paper, Documents,
Instruments or General Intangibles under the Uniform Commercial Code in effect
in any jurisdiction), in each case arising from the sale, lease, exchange or
other disposition of Inventory, and all of the Grantor's rights to any goods,
services or other property related to any of the foregoing (including returned
or repossessed goods and unpaid seller's rights of rescission, replevin,
reclamation and rights to stoppage in transit), and all collateral security and
supporting obligations of any kind given by any Person with respect to any of
the foregoing.

             "Receivables Collection Account" means (i) each Transferred
Receivables Collection Account and (ii) each Unsold Receivables Collection
Account.

             "Receivables Concentration Account" means (i) each Transferred
Receivables Concentration Account and (ii) the Unsold Receivables Concentration
Account.

             "Receivables SPV" means AK Steel Receivables Ltd., an Ohio limited
liability corporation and a wholly-owned indirect Subsidiary of the Company.

             "Receivables Termination Notice" means a "Receivables Termination
Notice" as defined in the Intercreditor Agreement, and any similar notice
delivered pursuant to any intercreditor agreement entered into after the Closing
Date with a Person purchasing Receivables or otherwise providing financing under
a Receivables Securitization Program.

             "Related Transferred Rights" has the meaning specified in Section
2(b) hereof.

             "Release Conditions" means the following conditions for terminating
all the Transaction Liens:

             (i)  all Commitments under the Credit Agreement shall have expired
     or been terminated;

                                      -4-                     SECURITY AGREEMENT

<PAGE>

             (ii) all Liquidated Secured Obligations shall have been paid in
     full; and

             (iii) no Unliquidated Secured Obligation shall remain outstanding
     or such Unliquidated Secured Obligation shall be cash collateralized to an
     extent and in a manner reasonably satisfactory to each affected Secured
     Party.

             "Returned Goods" has the meaning ascribed to such term in the
Intercreditor Agreement.

             "Secured Obligations" means the "Obligations" as defined in the
Credit Agreement (including, without limitation, the obligations of each of
Holdings and the Subsidiary Guarantors under their respective Guaranties, as
well as the obligations of the Company under the Credit Agreement).

             "Secured Parties" means the holders from time to time of the
Secured Obligations, and "Secured Party" means any of such holders as the
context may require.

             "Transaction Liens" means all Liens granted by the Grantor under
any of the Collateral Documents.

             "Transferred Receivables" means (i) the Purchased Receivables and
(ii) any now owned or hereafter existing Receivables sold, purported to be sold,
transferred or contributed, or purported to be transferred or contributed, prior
to the effective date of a Receivables Termination Notice, to an Eligible
Transferee in connection with a Permitted Receivables Securitization Program
that is not prohibited under the Credit Agreement or this Security Agreement,
prior to the full payment in cash of all amounts owing under such Permitted
Receivables Securitization Program and termination of the documents governing
such Permitted Receivables Securitization Program.

             "Transferred Receivables Collection Account" means (i) each
Purchased Receivables Collection Account and (ii) each deposit account serving a
similar function under a Permitted Receivables Securitization Program.

             "Transferred Receivables Concentration Account" means (i) the
Purchased Receivables Concentration Account and (ii) each deposit account
serving a similar function under a Permitted Receivables Securitization Program.

             "UCC" means the Uniform Commercial Code as in effect from time to
time in the State of New York; provided that, if perfection or the effect of
perfection or non-perfection or the priority of any Transaction Lien on any
Collateral is governed by the Uniform Commercial Code as in effect in a
jurisdiction other than New York, "UCC" means the Uniform Commercial Code as in
effect from time to time in such other jurisdiction for purposes of the
provisions hereof relating to such perfection, effect of perfection or
non-perfection or priority.

             "Unliquidated Secured Obligation" means, at any time, any Secured
Obligation (or portion thereof) that is contingent in nature or unliquidated at
such time, including any Secured Obligation that is:

                                      -5-                     SECURITY AGREEMENT

<PAGE>

             (i)  an obligation to reimburse a bank for drawings not yet made
     under a letter of credit issued by it;

             (ii) any other obligation (including any guaranty) that is
     contingent in nature at such time; or

             (iii) an obligation to provide collateral to secure any of the
     foregoing types of obligations.

             "Unsold Receivables" means any Receivables other than Transferred
Receivables.

             "Unsold Receivables Collection Account" means any Deposit Account
other than a Transferred Receivables Collection Account to which the Collateral
Agent directs or requests that obligors of Unsold Receivables make payments with
respect to such Unsold Receivables.

             "Unsold Receivables Concentration Account" means any Deposit
Account other than a Transferred Receivables Concentration Account into which
funds on deposit in an Unsold Receivables Collection Account (or other Proceeds
of Unsold Receivables) are swept.

             (d)  Terms Generally. The definitions of terms herein (including
those incorporated by reference to the UCC or to another document) apply equally
to the singular and plural forms of the terms defined. Whenever the context may
require, any pronoun includes the corresponding masculine, feminine and neuter
forms. The words "include", "includes" and "including" shall be deemed to be
followed by the phrase "without limitation". The word "will" shall be construed
to have the same meaning and effect as the word "shall". Unless the context
requires otherwise, (a) any definition of or reference to any agreement,
instrument or other document herein shall be construed as referring to such
agreement, instrument or other document as from time to time amended,
supplemented or otherwise modified (subject to any restrictions on such
amendments, supplements or modifications set forth herein), (b) any reference
herein to any Person shall be construed to include such Person's successors and
assigns, (c) the words "herein", "hereof" and "hereunder", and words of similar
import, shall be construed to refer to this Security Agreement in its entirety
and not to any particular provision hereof, (d) all references herein to
Sections, Annexes and Schedules shall be construed to refer to Sections of, and
Annexes and Schedules to, this Security Agreement and (e) the word "property"
shall be construed to refer to any and all tangible and intangible assets and
properties, including cash, securities, accounts and contract rights.

SECTION 2.   GRANT OF SECURITY INTERESTS.

             (a)  The Grantor, in order to secure the Secured Obligations,
grants to the Collateral Agent for the benefit of the Secured Parties a
continuing security interest in all the following property of the Grantor,
whether now owned or existing or hereafter acquired or arising and regardless of
where located, subject to the exceptions set forth in Section 2(b):

             (i)  all Inventory;

             (ii) all Receivables;

                                      -6-                     SECURITY AGREEMENT

<PAGE>

             (iii) all contracts for the sale, lease, exchange or other
     disposition of Inventory, whether or not performed and whether or not
     subject to termination upon a contingency or at the option of any party
     thereto;

             (iv) all Documents covering Inventory;

             (v)  the Collateral Account, the Proceeds Remittance Account, all
     right, title, and interest that the Grantor may have with respect to each
     Receivables Collection Account and each Receivables Concentration Account,
     and all right, title, and interest (if any) that the Grantor may have with
     respect to the Repayment Account, together with each other Deposit Account
     in which Proceeds of Inventory are deposited;

             (vi) all trademarks, servicemarks, trade names and similar
     intangible property owned or used by the Grantor in its business, together
     with the goodwill of the business symbolized thereby and all rights
     relating thereto (the "Intangible Property"); provided that the rights of
     the Collateral Agent and the Secured Parties with respect to the Intangible
     Property are limited to the use of such Intangible Property to manufacture,
     process and sell the Inventory;

             (vii) all books and records (including customer lists, credit
     files, computer programs, printouts and other computer materials and
     records) of the Grantor pertaining to any of the Collateral; and

             (viii) all other Proceeds of the Collateral described in the
     foregoing clauses (i) through (vii).

             (b)  The Collateral shall not include Receivables existing on the
Closing Date, Transferred Receivables, and (i) the Collections relating to such
Transferred Receivables, (ii) the interests of the Purchaser Agent and any
Eligible Transferee in any Returned Goods relating to such Transferred
Receivables, (iii) with respect to such Transferred Receivables, all rights,
interests and claims of the Eligible Transferee under the Permitted Receivables
Securitization Program in respect of such Transferred Receivables, (iv) each
deposit or other bank account to which any Collections of such Transferred
Receivables are deposited (to the extent that monies deposited in such accounts
are Collections related to Transferred Receivables) and (v) all Proceeds of the
items described in subclauses 2(b)(i) through 2(b)(iv) (all items described in
subclauses 2(b)(i) through 2(b)(v), collectively, the "Related Transferred
Rights"); provided, however, that nothing in this Section 2(b) shall exclude
from the Collateral or be deemed to constitute a release of: (I) any Transaction
Lien on the proceeds received by the Company from an Eligible Transferee for the
sale of Receivables pursuant to the Existing Receivables Purchase Agreement or
any other agreement serving a similar function under a Permitted Receivables
Securitization Program (including, without limitation, cash payments made by
such Eligible Transferee and the Subordinated AKR Note or any other instrument
serving a similar function under a Permitted Receivables Securitization Program
(as the outstanding principal balance under the Subordinated AKR Note or such
other instrument may increase or decrease from time to time)), (II) any
Transaction Lien on or right of any Agent or any of the Lenders in any interests
that the Company may acquire from an Eligible Transferee or the Purchaser Agent
(or

                                      -7-                     SECURITY AGREEMENT

<PAGE>

Person serving a similar role in any Permitted Receivables Securitization
Program) or that the Company has in Returned Goods, (III) any Transaction Lien
on or right that any of the Lenders or any Agent has in any Unsold Receivables
and the proceeds thereof, or (IV) any Transaction Lien on or right that any
Agent or any of the Lenders has in any deposit or other bank account under any
Deposit Agreement.

             (c)  With respect to each right to payment or performance included
in the Collateral from time to time, the Transaction Lien granted therein
includes a continuing security interest in all right, title and interest of the
Grantor in and to (i) any Supporting Obligation that supports such payment or
performance and (ii) any Lien that (x) secures such right to payment or
performance or (y) secures any such Supporting Obligation.

             (d)  The Transaction Liens are granted as security only and shall
not subject the Collateral Agent or any other Secured Party to, or transfer or
in any way affect or modify, any obligation or liability of the Grantor with
respect to any of the Collateral or any transaction in connection therewith.

SECTION 3.   REPRESENTATIONS AND WARRANTIES.

             The Grantor represents and warrants that:

             (a)  The Grantor is duly organized, validly existing and in good
standing under the laws of the jurisdiction identified as its jurisdiction of
organization in its Perfection Certificate.

             (b)  The Grantor has good and marketable title to all of the
Collateral (subject to exceptions that are, in the aggregate, not material),
free and clear of any Lien other than Permitted Liens.

             (c)  The Grantor has not performed any acts that might prevent the
Collateral Agent from enforcing any of the provisions of the Collateral
Documents or that would limit the Collateral Agent in any such enforcement
except as expressly permitted by the Loan Documents or consented to by any
Agent. No financing statement, security agreement, mortgage or similar or
equivalent document or instrument covering all or part of the Collateral is on
file or of record in any jurisdiction in which such filing or recording would be
effective to perfect or record a Lien on such Collateral, except financing
statements, mortgages or other similar or equivalent documents with respect to
Permitted Liens. After the Closing Date, no Collateral will be in the possession
or under the control of any other Person having a Lien thereon, other than a
Permitted Lien.

             (d)  The Transaction Liens on all Collateral (i) have been validly
created, (ii) will attach to each item of such Collateral on the Closing Date
(or, if the Grantor first obtains rights thereto on a later date, on such later
date) and (iii) when so attached, will secure all the Secured Obligations.

             (e)  The Grantor has delivered a Perfection Certificate to the
Collateral Agent. The information set forth therein is correct and complete as
of the Closing Date. After the Closing Date, the Collateral Agent or the
Administrative Agent may obtain, at the Grantor's

                                      -8-                     SECURITY AGREEMENT

<PAGE>

expense, a file search report from each UCC filing office listed in its
Perfection Certificate, showing the filing made at such filing office to perfect
the Transaction Liens on the Collateral.

             (f)  When UCC financing statements describing the Collateral as set
forth in the Grantor's Perfection Certificate have been filed in the offices
specified in the Perfection Certificate, the Transaction Liens will constitute
First Priority perfected security interests in the Collateral owned by the
Grantor to the extent that a security interest therein may be perfected by
filing pursuant to the UCC, prior to all Liens and rights of others therein
except Permitted Liens. Except for the filing of such UCC financing statements,
no registration, recordation or filing with any governmental body, agency or
official is required in connection with the execution or delivery of the
Collateral Documents or is necessary for the validity or enforceability thereof
or for the perfection of the Transaction Liens pursuant to the UCC or for the
enforcement of the Transaction Liens pursuant to the UCC.

             (g)  The Grantor has taken, and will continue to take, all actions
necessary under the UCC to perfect its interest in any Receivables purchased or
otherwise acquired by it, as against its assignors and creditors of its
assignors.

             (h)  The Collateral is insured as required by the Credit Agreement.

             (i)  Any Inventory produced by the Grantor has or will have been
produced in compliance with the applicable requirements of the Fair Labor
Standards Act, as amended.

             (j)  With respect to any Inventory scheduled or listed on the most
recent Borrowing Base Certificate delivered to the Collateral Agent pursuant to
the terms of the Credit Agreement, (i) except as specifically disclosed in the
most recent Borrowing Base Certificate delivered to the Collateral Agent, such
Inventory is Eligible Inventory of good and merchantable quality, free from any
defects, (ii) such Inventory is not subject to any licensing, patent, royalty,
trademark, trade name or copyright agreements with any third parties which would
require any consent of any third party upon sale or disposition of that
Inventory or the payment of any monies to any third party upon such sale or
other disposition and (iii) except for the rights of bailees, processors,
mortgagees and landlords from whom the Grantor is not required to obtain a
Bailee Consent, a Processor Consent, Mortgagee Consent or a Landlord Consent, as
applicable, under the terms of the Credit Agreement, the completion of
manufacture, sale or other disposition of such Inventory by the Collateral Agent
following an Event of Default shall not require the consent of any Person and
shall not constitute a breach or default under any contract or agreement to
which the Grantor is a party or to which such property is subject.

             (k)  No Deposit Accounts other than the Existing Receivables SPV
Deposit Accounts, the Transferor's Account, the SPV Remittance Account, the
Transferred Receivables Cash Collateral Account, and the "Agent's Account" (as
defined in the Existing Purchase and Servicing Agreement) are owned by the
Receivables SPV. Other than (i) the Existing Receivables SPV Deposit Accounts,
(ii) the Proceeds Remittance Account, (iii) the Unsold Receivables Collection
Accounts, (iv) the Unsold Receivables Concentration Account, (v) the Collateral
Account, and (vi) each lockbox, collection, concentration or similar deposit
account that has been subjected to a Deposit Agreement pursuant to Section 4(a),
there are no intervening

                                      -9-                     SECURITY AGREEMENT

<PAGE>

deposit accounts owned by such Grantor or the Receivables SPV into which any
collections or other payments or proceeds in respect of Receivables may be
deposited.

SECTION 4.   COVENANTS.

             The Grantor covenants as follows:

             (a)  The Grantor will, from time to time, at its own expense,
execute, deliver, authorize, file and record any statement, assignment,
instrument, document, agreement or other paper and take any other action
(including, without limitation, (x) any filing of financing or continuation
statements under the UCC, or amendments thereto, (y) causing any lockbox,
concentration or similar deposit account into which payments with respect to
Receivables then owned by the Grantor will be received to be subjected to
Deposit Agreements and (z) causing the appropriate parties to each Receivables
Securitization Program to execute an intercreditor agreement that is
substantially identical to the Intercreditor Agreement) that from time to time
may be reasonably necessary or desirable, or that the Administrative Agent or
the Collateral Agent may reasonably request, in order to:

             (i)  create, preserve, perfect, confirm or validate the First
     Priority Transaction Liens on the Collateral;

             (ii) enable the Collateral Agent and the other Secured Parties to
     obtain the full benefits of the Collateral Documents; or

             (iii) enable the Collateral Agent to exercise and enforce any of
     its rights, powers and remedies with respect to any of the Collateral.

             To the extent permitted by applicable law, the Grantor authorizes
the Collateral Agent to execute and file such financing statements or
continuation statements or amendments thereto without the Grantor's signature
appearing thereon. The Collateral Agent agrees to provide the Company with
copies of any such financing statements and continuation statements. The Grantor
agrees that a carbon, photographic, photostatic or other reproduction of this
Security Agreement or of a financing statement is sufficient as a financing
statement to the extent permitted by law. The Grantor constitutes the Collateral
Agent its attorney-in-fact to execute and file all filings required or so
requested for the foregoing purposes, all acts of such attorney being hereby
ratified and confirmed; and such power, being coupled with an interest, shall be
irrevocable until all the Transaction Liens granted by the Grantor terminate
pursuant to Section 12. The Company will pay the costs of, or incidental to, any
recording or filing of any financing or continuation statements or other
documents recorded or filed pursuant hereto.

             (b)  The Grantor will not (i) change its name or corporate
structure (or other form of organization), (ii) change its location (determined
as provided in UCC Section 9-307 or any successor provision) or become organized
under the laws of more than one jurisdiction or (iii) except with respect to a
Permitted Lien, become bound, as provided in UCC Section 9-203(d) or otherwise,
by a security agreement entered into by another Person, unless it shall have
given the Collateral Agent at least 20 days' prior written notice thereof and
delivered an Opinion of Counsel with respect thereto in accordance with Section
4(c).

                                      -10-                    SECURITY AGREEMENT

<PAGE>

             (c)  Before it takes any action contemplated by Section 4(b), the
Grantor, at its own expense, will cause to be delivered to the Collateral Agent
an Opinion of Counsel, in form and substance reasonably satisfactory to the
Collateral Agent (unless the requirement for such Opinion of Counsel is waived
by the Collateral Agent acting in its sole discretion); provided that it is
deemed to be reasonable for the Collateral Agent to require an Opinion to the
effect that (i) all financing statements and amendments or supplements thereto,
continuation statements and other documents required to be filed or recorded in
order to perfect and protect the Transaction Liens against all creditors of and
purchasers from the Grantor after it takes such action (except any applicable
continuation statements specified in such Opinion of Counsel that are to be
filed more than six months after the date thereof) have been filed or recorded
in each office necessary for such purpose, (ii) all fees and taxes, if any,
payable in connection with such filings or recordations have been paid in full
and (iii) except as otherwise agreed by Requisite Lenders, such action will not
adversely affect the perfection or priority of the Transaction Lien on any
Collateral to be owned by the Grantor after it takes such action or the accuracy
of the Grantor's representations and warranties herein relating to such
Collateral.

             (d)  The Grantor will not sell, lease, exchange, assign or
otherwise dispose of, or grant any option with respect to, any of its
Collateral; provided that the Grantor may do any of the foregoing unless (i)
doing so would breach a covenant in the Credit Agreement or (ii) an Event of
Default shall have occurred and be continuing and the Collateral Agent shall
have notified the Company that its right to do so is terminated, suspended or
otherwise limited. Concurrently with any sale or other disposition (except a
lease) permitted by the foregoing proviso, the Transaction Liens on the assets
sold or disposed of (but not in any Proceeds arising from such sale or
disposition, except as contemplated in Section 2(b)) will cease immediately
without any action by the Collateral Agent or any other Secured Party. The
Collateral Agent will, at the Company's expense, execute and deliver to the
Grantor such documents as the Grantor shall reasonably request to evidence the
fact that any asset so sold or disposed of is no longer subject to a Transaction
Lien.

             (e)  At all times no less than 85% (by value) of all Inventory of
the Grantor shall be either (x) located on property owned by the Company and its
Subsidiaries free and clear of mortgages, deeds of trust, deeds to secure debt,
and the like, or (y) covered by a Bailee Consent, Processor Consent, Landlord
Consent or Mortgagee Consent, as applicable. Grantor shall, within 10 days after
Collateral Agent's written request given from time to time, deliver to
Collateral Agent a true and accurate list of locations at which Inventory is
stored, in form and substance reasonably satisfactory to Collateral Agent.

             (f)  If the Grantor shall at any time hold or acquire any
negotiable Documents, Instruments or tangible Chattel Paper evidencing
Collateral, and such Document, Chattel Paper, or Instrument exceeds $200,000 on
an aggregate basis or $50,000 on an individual basis, the Grantor shall
forthwith endorse, assign and deliver the same to the Collateral Agent,
accompanied by such instruments of transfer or assignment duly executed in blank
as the Collateral Agent may from time to time specify. If the Grantor shall
retain possession of any Chattel Paper or Instruments with the Collateral
Agent's consent, and such Chattel Paper or Instrument exceeds $200,000 on an
aggregate basis or $50,000 on an individual basis, such Chattel Paper and
Instruments shall be marked with the following legend: "This writing and the
obligations evidenced or secured hereby are subject to the security interest of
General Electric

                                      -11-                    SECURITY AGREEMENT

<PAGE>

Capital Corporation, as Collateral Agent, for the benefit of itself and certain
Secured Parties." The Grantor shall take all steps necessary to grant the Agent
control of all electronic Chattel Paper in accordance with the UCC and all
"transferable records" as defined in each of the Uniform Electronic Transactions
Act and the Electronic Signatures in Global and National Commerce Act.

             (g)  The Grantor shall keep and maintain, at its own cost and
expense, satisfactory and complete records of the Collateral, including a record
of any and all payments received and any and all credits granted with respect to
the Collateral and all other dealings with the Collateral.

             (h)  The Grantor will, promptly upon request, provide to the
Collateral Agent all information and evidence concerning the Collateral that the
Collateral Agent may reasonably request from time to time to enable it to
enforce the provisions of the Collateral Documents.

             (i)  From time to time upon request by the Collateral Agent, the
Company will, at its own expense, cause to be delivered to the Secured Parties
an Opinion of Counsel satisfactory to the Collateral Agent as to such matters
relating to the transactions contemplated hereby as the Collateral Agent may
reasonably request.

SECTION 5.   DEPOSIT ACCOUNTS.

             (a)  (i) On or before the Closing Date, the Company shall establish
the Proceeds Remittance Account in the name of the Company and grant exclusive
dominion and control over the Proceeds Remittance Account to the Collateral
Agent pursuant to a Control Agreement. All amounts owned by the Grantor that are
to be deposited into the Proceeds Remittance Account from time to time pursuant
to the Loan Documents shall be deposited therein.

             (ii) The Collateral Agent is hereby authorized to establish and
maintain as a blocked account in the name of the Company and under the sole
dominion and control of the Collateral Agent, a restricted Deposit Account
designated as "AK Steel Credit Agreement 7/03 Collateral Account" (the
"Collateral Account"). All amounts at any time held in the Collateral Account
shall be beneficially owned by the Grantor but shall be held in the name of the
Collateral Agent hereunder, for the benefit of the Lenders, as collateral
security for the Secured Obligations upon the terms and conditions set forth
herein. The Grantor shall have no right to withdraw, transfer or, except as
expressly set forth herein, otherwise receive any funds deposited into the
Collateral Account. All deposits of funds in the Collateral Account shall be
made by wire transfer (or, if applicable, by intra-bank transfer from another
Deposit Account of Holdings or any of its Subsidiaries) of immediately available
funds, in each case addressed in accordance with instructions of Secured Party.
The Grantor shall, promptly after initiating a transfer of funds to the
Collateral Account, give notice to the Collateral Agent by telefacsimile of the
date, amount and method of delivery of such deposit. Cash held by the Collateral
Agent in the Collateral Account shall not be required to be invested by the
Collateral Agent but instead shall be maintained as a cash deposit in the
Collateral Account pending application thereof as elsewhere provided in this
Agreement; provided, however, that, the Collateral Account will be an
interest-bearing account and, subject to the Collateral Agent's rights
hereunder, any interest

                                      -12-                    SECURITY AGREEMENT

<PAGE>

earned on deposits of cash in the Collateral Account shall be deposited directly
in, and held in the Collateral Account.

             (b)  On or prior to August 15, 2003, the Company shall cause the
Receivables SPV to have subjected all of its then existing Purchased Receivables
Collection Accounts and Purchased Receivables Concentration Accounts
(collectively, the "Existing Receivables SPV Deposit Accounts") to Blocked
Account Agreements, each of which Blocked Account Agreements shall (i) by its
terms, transfer to the Collateral Agent sole dominion and control of the
relevant Purchased Receivables Collection Accounts or Purchased Receivables
Concentration Accounts, subject to receipt by the Depository Bank of written
notice from the Purchaser Agent, specifying that the Existing Receivables
Securitization Program has terminated and all monetary obligations in respect
thereof have been satisfied in full (or upon receipt by the Depository Bank of
written notice from the Collateral Agent to such effect, if (x) the
Administrative Agent or the Collateral Agent shall have delivered a Notification
Request (as defined in the Intercreditor Agreement), and (y) the Purchaser Agent
shall have failed to comply with such Notification Request within seven Business
Days of the date on which such Notification Request is effective under the
Intercreditor Agreement), (ii) expressly provide that its terms may not be
amended or modified without the consent of the Purchaser Agent until the
Existing Receivables Securitization Program has terminated and all monetary
obligations in respect thereof have been satisfied in full, and (iii) not
conflict with the Intercreditor Agreement. From time to time after the Closing
Date, the Company shall cause the Receivables SPV and each other Eligible
Transferee to subject each Transferred Receivables Collection Account and
Transferred Receivables Concentration Account to Blocked Account Agreements as
described above, so that all Transferred Receivables Collection Accounts and all
Transferred Receivables Concentration Accounts are subjected to Blocked Account
Agreements at all times.

             (c)  On or prior to the Closing Date, the Company shall cause the
Proceeds Remittance Account to be subjected to a Control Agreement. The Company
shall ensure that the Proceeds Remittance Account is subjected to a Control
Agreement at all times.

             (d)  The Company shall cause to be deposited in the Proceeds
Remittance Account, promptly upon receipt thereof, all payments from an Eligible
Transferee to the Company in respect of the purchase price of Transferred
Receivables, including, without limitation, all payments in respect of the
Subordinated AKR Note or any other instrument serving a similar function under a
Permitted Receivables Securitization Program. The Company shall designate the
Proceeds Remittance Account as the deposit account to which all payments shall
be made under Section 2.5(a) of the Existing Receivables Purchase Agreement. In
connection with any Permitted Receivables Securitization Program (other than the
Existing Receivables Securitization Program), the Company shall designate the
Proceeds Remittance Account as the deposit account to which payments to the
Company shall be made.

             (e)  Unless (i) The Cash Management System shall have been
activated with respect to the Proceeds Remittance Account pursuant to subsection
6.9 of the Credit Agreement and not de-activated with respect to the Proceeds
Remittance Account pursuant to such subsection, (ii) an Event of Default shall
have occurred and be continuing and Requisite Lenders shall have instructed the
Collateral Agent to stop permitting the Company to withdraw amounts from the
Proceeds Remittance Account pursuant to subsection 6.9A(i) of the Credit
Agreement

                                      -13-                    SECURITY AGREEMENT

<PAGE>

or (iii) the maturity of the Loans (or other Secured Obligations) shall have
been accelerated pursuant to Section 8 of the Credit Agreement (or otherwise),
the Company may withdraw amounts from the Proceeds Remittance Account from time
to time at will.

             (f)  (i) If an Event of Default shall have occurred and be
continuing, the Collateral Agent may (x) retain all cash and investments then
held in the Proceeds Remittance Account, (y) liquidate any or all investments
held therein and/or (z) withdraw any amounts held therein and apply such amounts
as provided in Section 7.

             (ii) Additionally, and without limiting the generality of the
foregoing, at any time when the Cash Management System is permitted to be
activated pursuant to subsection 6.9 of the Credit Agreement, the Collateral
Agent shall have the rights and obligations set forth in subsection 6.9 of the
Credit Agreement.

             (iii) Additionally, and without limiting the generality of the
foregoing, if an Event of Default shall have occurred and be continuing, at any
time after the effective date of any termination of transfers of Receivables
pursuant to Section 2.19 of the Intercreditor Agreement (or the equivalent
provision of any intercreditor agreement with respect to a Permitted Receivables
Securitization Program that replaces the Existing Receivables Securitization
Program), if an Event of Default has occurred and is continuing, the Collateral
Agent shall have the right (but no the obligation), to the extent permitted
under Section 2.04(c) of the Intercreditor Agreement (or the equivalent
provision of any intercreditor agreement with respect to a Permitted Receivables
Securitization Program that replaces the Existing Receivables Securitization
Program), to send notices to Obligors (as defined in the Intercreditor
Agreement) informing them of the Secured Parties' interest in the Receivables
and directing such Obligors (i) to make payments of any amounts due under the
Transferred Receivables to a Transferred Receivables Collection Account and (ii)
to make payments of any amounts due under the Unsold Receivables in any manner
consistent with the provisions of the Loan Documents determined by the
Collateral Agent in its reasonable credit judgment.

             (g)  Funds held in the Proceeds Remittance Account may, until
withdrawn or otherwise applied pursuant hereto, be invested and reinvested in
such Cash Equivalents as the Company shall request from time to time; provided
that, if an Event of Default shall have occurred and be continuing, the
Collateral Agent may select such Cash Equivalents.

             (h)  If immediately available cash on deposit in the Proceeds
Remittance Account is not sufficient to make any distribution or withdrawal to
be made pursuant hereto, the Collateral Agent will cause to be liquidated, as
promptly as practicable, such investments held in or credited to the Proceeds
Remittance Account as shall be required to obtain sufficient cash to make such
distribution or withdrawal and, notwithstanding any other provision hereof, such
distribution or withdrawal shall not be made until such liquidation has taken
place.

SECTION 6.   REMEDIES.

             (a)  If an Event of Default shall have occurred and be continuing,
the Collateral Agent may exercise (or cause its sub-agents to exercise) any or
all of the remedies available to it (or to such sub-agents) under the Collateral
Documents.

                                      -14-                    SECURITY AGREEMENT

<PAGE>

             (b)  Without limiting the generality of the foregoing, if an Event
of Default shall have occurred and be continuing, the Collateral Agent may
exercise on behalf of the Secured Parties all the rights of a secured party
under the UCC (whether or not in effect in the jurisdiction where such rights
are exercised) with respect to any Collateral and, in addition, the Collateral
Agent may, without being required to give any notice, except as herein provided
or as may be required by mandatory provisions of law, withdraw all cash held in
the Proceeds Remittance Account and apply such cash as provided in Section 7
and, if there shall be no such cash or if such cash shall be insufficient to pay
all the Secured Obligations in full, sell, lease, license or otherwise dispose
of the Collateral or any part thereof. Without limiting the generality of the
foregoing, the Grantor expressly agrees that in any such event the Collateral
Agent, without demand of performance or other demand, advertisement or notice of
any kind (except the notice specified below of time and place of public or
private sale) to or upon the Grantor or any other Person (all and each of which
demands, advertisements and notices are hereby expressly waived to the maximum
extent permitted by the UCC and other applicable law), may forthwith enter upon
the premises of the Grantor where any Collateral is located through self-help,
without judicial process, without first obtaining a final judgment or giving the
Grantor or any other Person notice and opportunity for a hearing on the
Collateral Agent's claim or action and may collect, receive, assemble, process,
appropriate and realize upon the Collateral, or any part thereof, and may
forthwith sell, lease, license, assign, give an option or options to purchase,
or sell or otherwise dispose of and deliver said Collateral (or contract to do
so), or any part thereof, in one or more parcels at a public or private sale or
sales, at any exchange at such prices as it may deem acceptable, for cash or on
credit or for future delivery without assumption of any credit risk. The
Collateral Agent or any Secured Party shall have the right upon any such public
sale or sales and, to the extent permitted by law, upon any such private sale or
sales, to purchase for the benefit of the Collateral Agent and Secured Parties,
the whole or any part of said Collateral so sold, free of any right or equity of
redemption, which equity of redemption the Grantor hereby releases. Such sales
may be adjourned and continued from time to time with or without notice. The
Collateral Agent shall have the right to conduct such sales on the Grantor's
premises or elsewhere and shall have the right to use the Grantor's premises
without charge for such time or times as the Collateral Agent deems necessary or
advisable for the purpose of realizing on the Collateral. If any Event of
Default shall have occurred and be continuing, the Grantor further agrees, at
the Collateral Agent's request, to assemble the Collateral and make it available
to the Collateral Agent at a place or places designated by the Collateral Agent
which are reasonably convenient to the Collateral Agent and the Grantor, whether
at the Grantor's premises or elsewhere. Until the Collateral Agent is able to
effect a sale, lease, or other disposition of Collateral, the Collateral Agent
shall have the right to hold or use the Collateral, or any part thereof, to the
extent that it deems appropriate for the purpose of realizing on or preserving
the Collateral or its value. The Collateral Agent shall have no obligation to
the Grantor to maintain or preserve the rights of the Grantor as against third
parties with respect to the Collateral while the Collateral is in the possession
of the Collateral Agent. The Collateral Agent may, if it so elects, seek the
appointment of a receiver or keeper to take possession of the Collateral and to
enforce any of the Collateral Agent's remedies (for the benefit of itself and
the Secured Parties), with respect to such appointment without prior notice or
hearing as to such appointment. The Collateral Agent shall apply the net
proceeds of any such collection, recovery, receipt, appropriation, realization
or sale to the Secured Obligations as provided in Section 7, and only after so
paying over such net proceeds, and after the payment by the Collateral Agent of
any

                                      -15-                    SECURITY AGREEMENT

<PAGE>

other amount required by any provision of law, need the Collateral Agent account
for the surplus, if any, to the Grantor. To the maximum extent permitted by
applicable law, the Grantor waives all claims, damages, and demands against the
Collateral Agent or any Secured Party arising out of the repossession, retention
or sale of the Collateral except such as arise solely out of the gross
negligence or willful misconduct of the Collateral Agent or such Secured Party,
or their respective agents, as finally determined by a court of competent
jurisdiction. The Grantor agrees that ten (10) days prior notice by the
Collateral Agent of the time and place of any public sale or of the time after
which a private sale may take place is reasonable notification of such matters
in accordance with Section 9. The Grantor shall remain liable for any deficiency
if the proceeds of any sale or disposition of the Collateral are insufficient to
pay all Secured Obligations, including any attorneys' fees and other expenses
incurred by the Collateral Agent or any Secured Party to collect such
deficiency.

             (c)  Without limiting the generality of the foregoing, at any time
when the Cash Management System is permitted to be activated pursuant to
subsection 6.9 of the Credit Agreement, the Collateral Agent may (i) exercise
all of the remedies described in Section 5(f)(ii) and (ii) cause all amounts
constituting Collateral that are held in any lockbox, collection, concentration
or other Deposit Account over which the Collateral Agent has the right to
exercise control pursuant to a Deposit Agreement (it being understood that any
Deposit Agreement with respect to a deposit account that is a Purchased
Receivables Collection Account or Purchased Receivables Concentration Account
shall only give the Collateral Agent the right to exercise control in accordance
with Section 5(b)(i)) to be transferred on a daily basis to the Repayment
Account.

             (d)  Without limiting the generality of the foregoing, if an Event
of Default shall have occurred and be continuing and, in accordance with Section
8 of the Credit Agreement, the Company is required to pay to Secured Party an
amount (the "Aggregate Available Amount") equal to 105% of the maximum amount
that may at any time be drawn under all Letters of Credit then outstanding under
the Credit Agreement, the Company shall deliver funds in such an amount for
deposit in the Collateral Account. If for any reason the aggregate amount
delivered by the Company for deposit in the Collateral Account as aforesaid is
less than the Aggregate Available Amount, the aggregate amount so delivered by
the Company shall be apportioned among all outstanding Letters of Credit for
purposes of this Section in accordance with the ratio of 105% of the maximum
amount available for drawing under each such Letter of Credit (as to such Letter
of Credit, the "Maximum Available Amount") to the Aggregate Available Amount.
Upon any drawing under any outstanding Letter of Credit in respect of which the
Company has deposited in the Collateral Account any amounts described above, the
Collateral Agent shall apply the amount apportioned to such Letter of Credit to
reimburse the Issuing Lender for the amount of such drawing. In the event of
cancellation or expiration of any Letter of Credit in respect of which the
Company has deposited in the Collateral Account any amounts described above, or
in the event of any reduction in the Maximum Available Amount under such Letter
of Credit, the Collateral Agent shall apply the amount then on deposit in the
Collateral Account in respect of such Letter of Credit (less, in the case of
such a reduction, the Maximum Available Amount under such Letter of Credit
immediately after such reduction) first, to the payment of any amounts payable
to the Collateral Agent pursuant to Section 8 hereof, second, to the extent of
any excess, to the cash collateralization pursuant to the terms of this Security
Agreement of any outstanding Letters of Credit in respect of which the Company
has failed to pay all or a

                                      -16-                    SECURITY AGREEMENT

<PAGE>

portion of the amounts described above (such cash collateralization to be
apportioned among all such Letters of Credit in the manner described above),
third, to the extent of any further excess, to the payment of any other
outstanding Secured Obligations in such order as the Collateral Agent shall
elect, and fourth, to the extent of any further excess, to the payment to
whomsoever shall be lawfully entitled to receive such funds.

             (e)  Without limiting the generality of the foregoing, if an Event
of Default shall have occurred and be continuing, each of the Administrative
Agent and the Requisite Lenders shall have the rights set forth in Section 2.19
of the Intercreditor Agreement (or the equivalent provision of any intercreditor
agreement with respect to a Permitted Receivables Securitization Program that
replaces the Existing Receivables Securitization Program).

             (f)  Neither the Collateral Agent nor the Secured Parties shall be
required to make any demand upon, or pursue or exhaust any of their rights or
remedies against, the Grantor, any other obligor, guarantor, pledgor or any
other Person with respect to the payment of the Secured Obligations or to pursue
or exhaust any of their rights or remedies with respect to any Collateral
therefor or any direct or indirect guarantee thereof. Neither the Collateral
Agent nor the Secured Parties shall be required to marshal the Collateral or any
guarantee of the Secured Obligations or to resort to the Collateral or any such
guarantee in any particular order, and all of its and their rights hereunder or
under any other Loan Document shall be cumulative. Each purchaser at any such
sale shall hold the property sold absolutely free from any claim or right on the
part of Grantors, and each Grantor hereby waives (to the extent permitted by
applicable law) all rights of redemption, stay and/or appraisal which it now has
or may at any time in the future have under any rule of law or statute now
existing or hereafter enacted. Each Grantor agrees that, to the extent notice of
sale shall be required by law, at least ten days' notice to such Grantor of the
time and place of any public sale or the time after which any private sale is to
be made shall constitute reasonable notification. Collateral Agent shall not be
obligated to make any sale of Collateral regardless of notice of sale having
been given. Collateral Agent may adjourn any public or private sale from time to
time by announcement at the time and place fixed therefor, and such sale may,
without further notice, be made at the time and place to which it was so
adjourned. Each Grantor hereby waives any claims against Collateral Agent
arising by reason of the fact that the price at which any Collateral may have
been sold at such a private sale was less than the price which might have been
obtained at a public sale, even if Collateral Agent accepts the first offer
received and does not offer such Collateral to more than one offeree. If the
proceeds of any sale or other disposition of the Collateral are insufficient to
pay all the Secured Obligations, Grantors shall be jointly and severally liable
for the deficiency and the fees of any attorneys employed by Collateral Agent to
collect such deficiency.

             (g)  Subject to any limitation on the rights of the Collateral
Agent under the Intercreditor Agreement, the Collateral Agent may at any time
after an Event of Default has occurred and is continuing without prior notice to
the Grantor, notify Account Debtors and other Persons obligated on the
Collateral that the Collateral Agent has a security interest therein, and that
payments shall be made directly to the Collateral Agent. At any time after an
Event of Default has occurred and is continuing, upon the request of the Agent,
Grantor shall so notify Account Debtors and other Persons obligated on
Collateral. Once any such notice has been given to any Account Debtor or other
Person obligated on the Collateral, the Grantor shall not, so

                                      -17-                    SECURITY AGREEMENT

<PAGE>

long as an Event of Default is continuing, give any contrary instructions to
such Account Debtor or other Person without the Collateral Agent's prior written
consent.

             (h)  Subject to any limitation on the rights of the Collateral
Agent under the Intercreditor Agreement, if an Event of Default has occurred and
is continuing, or if Company has failed to provide the information described in
this subparagraph (h) within 5 Business Days after Collateral Agent's request,
the Collateral Agent may in the Collateral Agent's own name, in the name of a
nominee of the Collateral Agent or in the name of the Grantor communicate (by
mail, telephone, facsimile or otherwise) with Account Debtors, parties to
contracts and obligors in respect of Instruments to verify with such Persons, to
the Collateral Agent's satisfaction, the existence, amount, terms of, and any
other matter relating to, Receivables, Instruments or Chattel Paper. If an Event
of Default shall have occurred and be continuing, the Grantor, at its own
expense, shall cause the independent certified public accountants then engaged
by the Grantor to prepare and deliver to the Collateral Agent at any time and
from time to time promptly upon the Collateral Agent's request the following
reports with respect to Grantor: (i) a reconciliation of all Receivables; (ii)
an aging of all Receivables; (iii) trial balances; and (iv) a test verification
of such Receivables as Agent may request. The Grantor, at its own expense, shall
deliver to the Collateral Agent the results of each physical verification, if
any, which the Grantor may in its discretion have made, or caused any other
Person to have made on its behalf, of all or any portion of its Inventory.

SECTION 7.   APPLICATION OF PAYMENTS.

             (a)  If an Event of Default shall have occurred and be continuing,
the Collateral Agent may apply (i) any cash held in the Proceeds Remittance
Account and (ii) the proceeds of any sale or other disposition of all or any
part of the Collateral, in the order of priorities required by subsection 2.4C
of the Credit Agreement. The Collateral Agent may make such distributions
hereunder in cash or in kind or, on a ratable basis, in any combination thereof.

             (b)  If at any time any portion of any monies collected or received
by the Collateral Agent would, but for the provisions of this Section 7(b), be
payable pursuant to Section 7(a) in respect of an Unliquidated Secured
Obligation, the Collateral Agent shall not apply any monies to pay such
Unliquidated Secured Obligation but instead shall request the holder thereof to
notify the Collateral Agent as to the maximum amount of such Unliquidated
Secured Obligation if then ascertainable (e.g., in the case of a letter of
credit, the maximum amount available for subsequent drawings thereunder). If the
holder of such Unliquidated Secured Obligation does not notify the Collateral
Agent of the maximum ascertainable amount thereof at least two Business Days
before such distribution, such Unliquidated Secured Obligation will not be
entitled to share in such distribution. If such holder does so notify the
Collateral Agent as to the maximum ascertainable amount thereof, and if such
Unliquidated Secured Obligation is not fully cash collateralized pursuant to
Section 6(d), the Collateral Agent will allocate to such holder a portion of the
monies to be distributed in such distribution, calculated as if such
Unliquidated Secured Obligation were outstanding in such maximum ascertainable
amount. However, the Collateral Agent will not apply such portion of such monies
to pay such Unliquidated Secured Obligation, but instead will hold such monies
or invest such monies in Cash Equivalents. All such monies and Cash Equivalents
and all proceeds thereof will constitute Collateral hereunder, but will be
subject to distribution in accordance with this

                                      -18-                    SECURITY AGREEMENT

<PAGE>

Section 7(b) rather than Section 7(a). The Collateral Agent will hold all such
monies and Cash Equivalents and the net proceeds thereof in trust until all or
part of such Unliquidated Secured Obligation becomes a Liquidated Secured
Obligation, whereupon the Collateral Agent at the request of the relevant
Secured Party will apply the amount so held in trust to pay such Liquidated
Secured Obligation; provided that, if the other Secured Obligations theretofore
paid pursuant to the same clause of subsection 2.4C of the Credit Agreement were
not paid in full, the Collateral Agent will apply the amount so held in trust to
pay the same percentage of such Liquidated Secured Obligation as the percentage
of such other Secured Obligations theretofore paid pursuant to the same clause
of subsection 2.4C of the Credit Agreement. If (i) the holder of such
Unliquidated Secured Obligation shall advise the Collateral Agent that no
portion thereof remains in the category of an Unliquidated Secured Obligation
and (ii) the Collateral Agent still holds any amount held in trust pursuant to
this Section 7(b) in respect of such Unliquidated Secured Obligation (after
paying all amounts payable pursuant to the preceding sentence with respect to
any portions thereof that became Liquidated Secured Obligations), such remaining
amount will be applied by the Collateral Agent in the order of priorities set
forth in subsection 2.4C of the Credit Agreement.

             (c)  In making the payments and allocations required by this
Section, the Collateral Agent may rely upon information supplied to it pursuant
to Section 11(g). All distributions made by the Collateral Agent pursuant to
this Section shall be final (except in the event of manifest error) and the
Collateral Agent shall have no duty to inquire as to the application by any
Secured Party of any amount distributed to it.

SECTION 8.   TAXES, FEES AND EXPENSES.

             (a)  Without in any way limiting the terms of Sections 2.7B, 11.2
or 11.3 of the Credit Agreement, the Grantor shall forthwith upon demand pay to
the Collateral Agent:

             (i)  the amount of any taxes that the Collateral Agent may have
     been required to pay by reason of the Transaction Liens or to free any
     Collateral from any other Lien thereon;

             (ii) the amount of any and all reasonable out-of-pocket expenses,
     including transfer taxes and reasonable fees and expenses of counsel and
     other experts, that the Collateral Agent may incur in connection with (x)
     the administration or enforcement of the Collateral Documents, including
     such expenses as are incurred to preserve the value of the Collateral or
     the validity, perfection, rank or value of any Transaction Lien, (y) the
     collection, sale or other disposition of any Collateral or (z) the exercise
     by the Collateral Agent of any of its rights or powers under the Collateral
     Documents;

             (iii) the amount of any fees that the Grantor shall have agreed in
     writing to pay to the Collateral Agent and that shall have become due and
     payable in accordance with such written agreement; and

             (iv) the amount required to indemnify the Collateral Agent for, or
     hold it harmless and defend it against, any loss, liability or expense
     (including the

                                      -19-                    SECURITY AGREEMENT

<PAGE>

     reasonable fees and expenses of its counsel and any experts or sub-agents
     appointed by it hereunder) incurred or suffered by the Collateral Agent in
     connection with the Collateral Documents, except to the extent that such
     loss, liability or expense arises from the Collateral Agent's gross
     negligence or willful misconduct as determined by a final judgment of a
     court of competent jurisdiction or a breach of any duty that the Collateral
     Agent has under this Security Agreement (after giving effect to Sections 10
     and 11). Any such amount not paid to the Collateral Agent on demand will
     bear interest for each day thereafter until paid at a rate per annum equal
     to the sum of 2.00% plus the Base Rate for such day plus the Base Rate
     Margin that would, in the absence of an Event of Default, be applicable to
     the Base Rate Loans for such day.

             (b)  If any transfer tax, documentary stamp tax or other tax is
payable in connection with any transfer or other transaction provided for in the
Collateral Documents, the Grantor will pay such tax and provide any required tax
stamps to the Collateral Agent or as otherwise required by law.

SECTION 9.   POWER OF ATTORNEY.

             On the Closing Date the Grantor shall execute and deliver to the
Collateral Agent a power of attorney (the "Power of Attorney") substantially in
the form attached hereto as Annex B. The power of attorney granted pursuant to
the Power of Attorney is a power coupled with an interest and shall be
irrevocable until all Release Conditions have been satisfied. The powers
conferred on the Collateral Agent, for the benefit of the Collateral Agent and
the Secured Parties, under the Power of Attorney are solely to protect the
Collateral Agent's interests (for the benefit of the Collateral Agent and the
Secured Parties) in the Collateral and shall not impose any duty upon the
Collateral Agent or any Secured Party to exercise any such powers. The
Collateral Agent agrees that notwithstanding any provision of the Power of
Attorney, (a) except for the powers granted in clause (h) of the Power of
Attorney, it shall not exercise any power or authority granted under the Power
of Attorney unless an Event of Default has occurred and is continuing, (b) it
shall only exercise the powers and authority granted under the Power of Attorney
to protect the Collateral Agent's interests (for the benefit of the Collateral
Agent and the Secured Parties) in the Collateral, and (c) the Collateral Agent
shall account for any moneys received by the Collateral Agent in respect of any
foreclosure on or disposition of Collateral pursuant to the Power of Attorney;
provided that none of the Collateral Agent nor any Secured Party shall have any
duty as to any Collateral, and the Collateral Agent and the Secured Parties
shall be accountable only for amounts they actually receive as a result of the
exercise of such powers. NONE OF THE COLLATERAL AGENT, THE SECURED PARTIES OR
THEIR RESPECTIVE AFFILIATES, OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR
REPRESENTATIVES SHALL BE RESPONSIBLE TO THE GRANTOR FOR ANY ACT OR FAILURE TO
ACT UNDER ANY POWER OF ATTORNEY OR OTHERWISE, EXCEPT IN RESPECT OF DAMAGES
ATTRIBUTABLE SOLELY TO THEIR OWN GROSS NEGLIGENCE OR WILLFUL MISCONDUCT AS
FINALLY DETERMINED BY A COURT OF COMPETENT JURISDICTION, NOR FOR ANY PUNITIVE,
EXEMPLARY, INDIRECT OR CONSEQUENTIAL DAMAGES.

                                      -20-                    SECURITY AGREEMENT

<PAGE>
SECTION 10.  LIMITED DUTY.

             Beyond the exercise of reasonable care in the custody and
preservation thereof, the Collateral Agent will have no duty as to any
Collateral in its possession or control or in the possession or control of any
sub-agent or bailee or any income therefrom or as to the preservation of rights
against prior parties or any other rights pertaining thereto. The Collateral
Agent will be deemed to have exercised reasonable care in the custody and
preservation of the Collateral in its possession or control if such Collateral
is accorded treatment substantially equal to that which it accords its own
property, and will not be liable or responsible for any loss or damage to any
Collateral, or for any diminution in the value thereof, by reason of any act or
omission of any sub-agent or bailee selected by the Collateral Agent in good
faith or by reason of any act or omission by the Collateral Agent pursuant to
instructions from the Administrative Agent, except to the extent that such
liability arises from the Collateral Agent's gross negligence or willful
misconduct as determined by a final judgment of a court of competent
jurisdiction.

SECTION 11.  RIGHTS OF COLLATERAL AGENT.

             Without in any way limiting the rights of the Collateral Agent set
forth in Section 10 of the Credit Agreement:

             (a)  Authority. The Collateral Agent is authorized to take such
actions and to exercise such powers as are delegated to the Collateral Agent by
the terms of Credit Agreement and the Collateral Documents, together with such
actions and powers as are reasonably incidental thereto.

             (b)  Coordination with Secured Parties. To the extent requested to
do so by any Secured Party, the Collateral Agent will promptly notify such
Secured Party of each notice or other communication received by the Collateral
Agent hereunder and/or deliver a copy thereof to such Secured Party. As to any
matters not expressly provided for herein (including (i) the timing and methods
of realization upon the Collateral and (ii) the exercise of any power that the
Collateral Agent may, but is not expressly required to, exercise under any
Security Document), the Collateral Agent shall act or refrain from acting in
accordance with written instructions from Requisite Lenders or, in the absence
of such instructions, in accordance with its discretion (subject to the
following provisions of this Section).

             (c)  Rights and Powers as a Secured Party. The Person serving as
the Collateral Agent shall, in its capacity as a Secured Party, have the same
rights and powers as any other Secured Party and may exercise the same as though
it were not the Collateral Agent. Such Person and its Affiliates may accept
deposits from, lend money to and generally engage in any kind of business with
the Company, any of its Subsidiaries or their respective Affiliates as if it
were not the Collateral Agent hereunder.

             (d)  Limited Duties and Responsibilities. The Collateral Agent
shall not have any duties or obligations under the Collateral Documents except
those expressly set forth therein. Without limiting the generality of the
foregoing, (a) the Collateral Agent shall not be subject to any fiduciary or
other implied duties, regardless of whether an Event of Default has occurred and
is continuing, (b) the Collateral Agent shall not have any duty to take any
discretionary action or

                                      -21-                    SECURITY AGREEMENT

<PAGE>

exercise any discretionary powers, except discretionary rights and powers
expressly contemplated by the Collateral Documents that the Collateral Agent is
required in writing to exercise by Requisite Lenders, and (c) except as
expressly set forth in the Collateral Documents, the Collateral Agent shall not
have any duty to disclose, and shall not be liable for any failure to disclose,
any information relating to the Company or any of its Subsidiaries that is
communicated to or obtained by the institution serving as Collateral Agent or
any of its Affiliates in any capacity. The Collateral Agent shall not be liable
for any action taken or not taken by it with the consent or at the request of
Requisite Lenders (or such other number or percentage of the Lenders as shall be
necessary under the circumstances as provided in the Credit Agreement) or in the
absence of its own gross negligence or willful misconduct as determined by a
final judgment of a court of competent jurisdiction. The Collateral Agent shall
not be responsible for the existence, genuineness or value of any Collateral or
for the validity, perfection, priority or enforceability of any Transaction
Lien, whether impaired by operation of law or by reason of any action or
omission to act on its part under the Collateral Documents. The Collateral Agent
shall be deemed not to have knowledge of any Event of Default unless and until
written notice thereof is given to the Collateral Agent by the Company or a
Secured Party, and the Collateral Agent shall not be responsible for or have any
duty to ascertain or inquire into (i) any statement, warranty or representation
made in or in connection with any Security Document, (ii) the contents of any
certificate, report or other document delivered thereunder or in connection
therewith, (iii) the performance or observance of any of the covenants,
agreements or other terms or conditions set forth in any Security Document, (iv)
the validity, enforceability, effectiveness or genuineness of any Security
Document or any other agreement, instrument or document, or (v) the satisfaction
of any condition set forth in any Security Document.

             (e)  Authority to Rely on Certain Writings, Statements and Advice.
The Collateral Agent shall be entitled to rely on, and shall not incur any
liability for relying on, any notice, request, certificate, consent, statement,
instrument, document or other writing believed by it to be genuine and to have
been signed or sent by the proper Person. The Collateral Agent also may rely on
any statement made to it orally or by telephone and believed by it to be made by
the proper Person, and shall not incur any liability for relying thereon. The
Collateral Agent may consult with legal counsel (who may be counsel for the
Company or any of its Subsidiaries), independent accountants and other experts
selected by it, and shall not be liable for any action taken or not taken by it
in accordance with the advice of any such counsel, accountant or expert. The
Collateral Agent may rely conclusively on advice from the Administrative Agent
as to whether at any time (i) an Event of Default under the Credit Agreement has
occurred and is continuing, (ii) the maturity of the Loans has been accelerated
or (iii) any proposed action is permitted or required by the Credit Agreement.

             (f)  Sub-Agents and Related Parties. The Collateral Agent may
perform any of its duties and exercise any of its rights and powers through one
or more sub-agents appointed by it. The Collateral Agent and any such sub-agent
may perform any of its duties and exercise any of its rights and powers through
its Related Parties. Supplemental Collateral Agents may be appointed in
accordance with subsection 10.1C of the Credit Agreement. The exculpatory
provisions of Section 10 and this Section shall apply to any such sub-agent or
Supplemental Collateral Agent and to the related parties of the Collateral Agent
and any such sub-agent or Supplemental Collateral Agent.

                                      -22-                    SECURITY AGREEMENT

<PAGE>

             (g)  Information as to Secured Obligations and Actions by Secured
Parties. For all purposes of the Collateral Documents, including determining the
amounts of the Secured Obligations and whether a Secured Obligation is an
Unliquidated Secured Obligation or not, or whether any action has been taken
under any Loan Document, the Collateral Agent will be entitled to rely on
information from (i) the Administrative Agent for information as to the Lenders,
the Administrative Agent or the Collateral Agent, their Secured Obligations and
actions taken by them, (ii) any Secured Party for information as to its Secured
Obligations and actions taken by it, to the extent that the Collateral Agent has
not obtained such information from the foregoing sources, and (iii) the Company,
to the extent that the Collateral Agent has not obtained information from the
foregoing sources.

             (h)  Within two Business Days after it receives or sends any notice
referred to in this subsection, the Collateral Agent shall send to the
Administrative Agent and each Secured Party requesting notice thereof, copies of
any notice given by the Collateral Agent to the Grantor, or received by it from
the Grantor, pursuant to Section 6, 7, 9, 11(j) or 12; provided that such
Secured Party has, at least five Domestic Business Days prior thereto, delivered
to the Collateral Agent a written notice (i) stating that it holds one or more
Secured Obligations and wishes to receive copies of such notices and (ii)
setting forth its address, facsimile number and e-mail address to which copies
of such notices should be sent.

             (i)  The Collateral Agent may refuse to act on any notice, consent,
direction or instruction from the Administrative Agent or any Secured Parties or
any agent, trustee or similar representative thereof that, in the Collateral
Agent's opinion, (i) is contrary to law or the provisions of any Security
Document, (ii) may expose the Collateral Agent to liability (unless the
Collateral Agent shall have been indemnified, to its reasonable satisfaction,
for such liability by the Secured Parties that gave, or instructed the
Collateral Agent to give, such notice, consent, direction or instruction) or
(iii) is unduly prejudicial to Secured Parties not joining in such notice,
consent, direction or instruction.

             (j)  Resignation; Successor Collateral Agent. The Collateral Agent
may resign, and a successor Collateral Agent may be appointed, in each case in
accordance with subsection 10.5 of the Credit Agreement.

SECTION 12.  RELEASE OF COLLATERAL.

             (a)  The Transaction Liens shall terminate when all the Release
Conditions are satisfied.

             (b)  The Transaction Liens (x) with respect to any Pledged
Receivables shall terminate when such Receivables have become Transferred
Receivables (subject to the Collateral Agent's continuing interest therein as
described in Section 2(b)) and (y) with respect to any other Collateral shall
terminate upon the sale of such Collateral to a Person other than Holdings or
any of its Subsidiaries in a transaction not prohibited by the Credit Agreement.
In each case, such termination shall not require the consent of any Secured
Party, and the Collateral Agent and any third party shall be fully protected in
relying on a certificate of the Grantor as to whether any Pledged Receivables
qualify as Transferred Receivables (including without limitation whether the
transfer thereof is permitted under the Credit Agreement and this Security
Agreement).

                                      -23-                    SECURITY AGREEMENT

<PAGE>

             (c)  In the case of any Pledged Receivables, the Transaction Liens
with respect to the Related Transferred Rights shall terminate when such Pledged
Receivables become Transferred Receivables (subject to the Collateral Agent's
continuing interest therein as described in Section 2(b)). Such termination
shall not require the consent of any Secured Party. If the Company delivers a
certificate pursuant to Section 12(b) stating that any Pledged Receivables
qualify as Transferred Receivables, the Collateral Agent and any third party
shall be fully protected in relying on such certificate as conclusive proof that
the Related Transferred Rights are not Collateral.

             (d)  At any time before the Transaction Liens terminate, the
Collateral Agent may, at the written request of the Grantor, (i) release any
Collateral (but not all or substantially all of the Collateral) with the prior
written consent of Requisite Lenders or (ii) release all or substantially all of
the Collateral with the prior written consent of all the Lenders.

             (e)  Upon any termination of a Transaction Lien or release of
Collateral, the Collateral Agent will, at the expense of the Grantor, execute
and deliver to the Grantor such documents as the Grantor shall reasonably
request to evidence the termination of such Transaction Lien or the release of
such Collateral, as the case may be.

SECTION 13.  NOTICES.

             Except in the case of notices and other communications expressly
permitted to be given by telephone, each notice, request or other communication
given to any party hereunder shall be in writing delivered by hand or overnight
courier service, mailed by certified or registered mail or sent by telecopy (or,
in the case of any notice to a Secured Party pursuant to Section 11(b) or
Section 11(h), transmitted by e-mail), to the address of the relevant party in
accordance with subsection 11.8 of the Credit Agreement.

             All notices and other communications given to any party hereto in
accordance with the terms of this Security Agreement shall be deemed to have
been given on the date of receipt. Any party may change its address, facsimile
number and/or e-mail address for purposes of this Section by giving notice of
such change to the Collateral Agent and the Grantor in the manner specified
above.

SECTION 14.  NO IMPLIED WAIVER; REMEDIES CUMULATIVE.

             No failure by the Collateral Agent or any Secured Party to
exercise, and no delay in exercising and no course of dealing with respect to,
any right or remedy under any Loan Document shall operate as a waiver thereof;
nor shall any single or partial exercise by the Collateral Agent or any Secured
Party of any right or remedy under any Loan Document preclude any other or
further exercise thereof or the exercise of any other right or remedy. The
rights and remedies specified in the Loan Documents are cumulative and are not
exclusive of any other rights or remedies provided by law.

SECTION 15.  BENEFIT OF AGREEMENT.

             This Security Agreement is for the benefit of the Collateral Agent
and the Secured Parties. If all or any part of any Secured Party's interest in
any Secured Obligation is assigned or

                                      -24-                    SECURITY AGREEMENT

<PAGE>

otherwise transferred, the transferor's rights hereunder, to the extent
applicable to the obligation so transferred, shall be automatically transferred
with such obligation. This Security Agreement shall be binding on the Grantor
and its successors and assigns.

SECTION 16.  AMENDMENTS, CONSENTS AND WAIVERS.

             Neither this Security Agreement nor any provision hereof may be
waived, amended, modified or terminated except pursuant to an agreement or
agreements in writing entered into by the parties hereto, with the consent of
such Lenders as are required to consent thereto under the Credit Agreement.

SECTION 17.  GOVERNING LAW.

             This Security Agreement shall be construed in accordance with and
governed by the laws of the State of New York, except as otherwise required by
mandatory provisions of law and except to the extent that remedies provided by
the laws of any jurisdiction other than the State of New York are governed by
the laws of such jurisdiction.

SECTION 18.  WAIVER OF JURY TRIAL.

             EACH PARTY HERETO WAIVES, TO THE FULLEST EXTENT PERMITTED BY
APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING
DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO ANY SECURITY DOCUMENT OR
ANY TRANSACTION CONTEMPLATED THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY
OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR
ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH
OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING
WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN
INDUCED TO ENTER INTO THIS SECURITY AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL
WAIVERS AND CERTIFICATIONS IN THIS SECTION.

SECTION 19.  SEVERABILITY.

             If any provision of any Security Document is invalid or
unenforceable in any jurisdiction, then, to the fullest extent permitted by law,
(i) the other provisions of the Collateral Documents shall remain in full force
and effect in such jurisdiction and shall be liberally construed in favor of the
Collateral Agent and the Secured Parties in order to carry out the intentions of
the parties thereto as nearly as may be possible and (ii) the invalidity or
unenforceability of such provision in such jurisdiction shall not affect the
validity or enforceability thereof in any other jurisdiction.

SECTION 20.  REINSTATEMENT.

             This Agreement shall remain in full force and effect and continue
to be effective should any petition be filed by or against the Grantor for
liquidation or reorganization, should the Grantor become insolvent or make an
assignment for the benefit of any creditor or creditors or

                                      -25-                    SECURITY AGREEMENT

<PAGE>

should a receiver or trustee be appointed for all or any significant part of the
Grantor's assets, and shall continue to be effective or be reinstated, as the
case may be, if at any time payment and performance of the Secured Obligations,
or any part thereof, is, pursuant to applicable law, rescinded or reduced in
amount, or must otherwise be restored or returned by any obligee of the Secured
Obligations, whether as a "voidable preference," "fraudulent conveyance," or
otherwise, all as though such payment or performance had not been made. In the
event that any payment, or any part thereof, is rescinded, reduced, restored or
returned, the Secured Obligations shall be reinstated and deemed reduced only by
such amount paid and not so rescinded, reduced, restored or returned.

SECTION 21.  CONSENT TO JURISDICTION AND SERVICE OF PROCESS.

             ALL JUDICIAL PROCEEDINGS BROUGHT AGAINST GRANTOR ARISING OUT OF OR
RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT, OR ANY OBLIGATIONS
THEREUNDER, MAY BE BROUGHT IN ANY STATE OR FEDERAL COURT OF COMPETENT
JURISDICTION IN THE STATE, COUNTY AND CITY OF NEW YORK. BY EXECUTING AND
DELIVERING THIS AGREEMENT, GRANTOR, FOR ITSELF AND IN CONNECTION WITH ITS
PROPERTIES, IRREVOCABLY

                  (i)   ACCEPTS GENERALLY AND UNCONDITIONALLY THE NONEXCLUSIVE
                        JURISDICTION AND VENUE OF SUCH COURTS;

                  (ii)  WAIVES ANY DEFENSE OF FORUM NON CONVENIENS;

                  (iii) AGREES THAT SERVICE OF ALL PROCESS IN ANY SUCH
                        PROCEEDING IN ANY SUCH COURT MAY BE MADE BY REGISTERED
                        OR CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO GRANTOR
                        AT ITS ADDRESS PROVIDED IN ACCORDANCE WITH SUBSECTION
                        11.8 OF THE CREDIT AGREEMENT;

                  (iv)  AGREES THAT SERVICE AS PROVIDED IN CLAUSE (III) ABOVE IS
                        SUFFICIENT TO CONFER PERSONAL JURISDICTION OVER GRANTOR
                        IN ANY SUCH PROCEEDING IN ANY SUCH COURT, AND OTHERWISE
                        CONSTITUTES EFFECTIVE AND BINDING SERVICE IN EVERY
                        RESPECT;

                  (v)   AGREES THAT SECURED PARTIES RETAIN THE RIGHT TO SERVE
                        PROCESS IN ANY OTHER MANNER PERMITTED BY LAW OR TO BRING
                        PROCEEDINGS AGAINST GRANTOR IN THE COURTS OF ANY OTHER
                        JURISDICTION; AND

                                      -26-                    SECURITY AGREEMENT

<PAGE>

AGREES THAT THE PROVISIONS OF THIS SECTION 21 RELATING TO JURISDICTION AND VENUE
SHALL BE BINDING AND ENFORCEABLE TO THE FULLEST EXTENT PERMISSIBLE UNDER NEW
YORK GENERAL OBLIGATIONS LAW SECTION 5-1402 OR OTHERWISE.

                                    * * * * *

                                      -27-                    SECURITY AGREEMENT

<PAGE>

             IN WITNESS WHEREOF, the parties hereto have caused this Security
Agreement to be duly executed by their respective authorized officers as of the
day and year first written above.

                                       AK STEEL CORPORATION

                                       By:       /s/  James L. Wainscott
                                          --------------------------------------
                                                    James L. Wainscott
                                                 Senior Vice President and
                                                  Chief Financial Officer

                                       GENERAL ELECTRIC CAPITAL CORPORATION,
                                       as Collateral Agent

                                       By:         /s/  John L. Dale
                                          --------------------------------------
                                                      John L. Dale
                                                Duly Authorized Signatory

                                       CREDIT SUISSE FIRST BOSTON,
                                       acting through its Cayman Islands branch,
                                       as Administrative Agent

                                       By:      /s/  Joseph J. Adipietro
                                          --------------------------------------
                                                    Joseph Adipietro
                                                        Director

                                       and

                                       By:         /s/  Kevin S. Smith
                                          --------------------------------------
                                                       Kevin Smith
                                                    Managing Director

                                                              SECURITY AGREEMENTCollaborative Development Agreement

 Exhibit 10.34 
  
 COLLABORATIVE DEVELOPMENT AGREEMENT 
  
 This Agreement is made and entered into this 30th day of August, 2000 by and between PHARMANETICS, INC., a North Carolina corporation (“PharmaNetics”), and AVENTIS PHARMACEUTICALS PRODUCTS INC., a
Delaware corporation (“Aventis”). PharmaNetics and Aventis are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 
  
 RECITALS 
  
 WHEREAS, PharmaNetics is an in-vitro diagnostic manufacturer that markets analyzer test cards for certain blood markers to be used with card
analyzer instrumentation systems; and 
  
 WHEREAS, Aventis
is a global pharmaceutical company that desires to have PharmaNetics develop and gain approval of an enoxaparin test card and analysis devices and to manufacture and supply such test cards and devices to exclusively support Lovenox® in the Territory.  
  
 NOW, THEREFORE, in consideration of the foregoing and the covenants
and promises contained in this Agreement, the Parties agree as follows: 
  
 ARTICLE 1 
  
 DEFINITIONS. 
  
 As used herein, the following terms shall have the following meanings: 
  

	1.1	 	“Act” means the Federal Food, Drug and Cosmetic Act of 1938, as the same may be amended or re-enacted from time to time. 

  

	1.2	 	“Affiliate” means a corporation, partnership, trust or other entity that directly, or indirectly through one or more intermediates, controls, is controlled by or is
under common control with a Party to this Agreement. For such purposes, “control,” “controlled by” and “under common control with” shall mean the possession of the power to direct or cause the direction of the
management and policies of an entity, whether through the ownership of voting stock or partnership interest, by contract or otherwise. In the case of a corporation, the direct or indirect ownership of more than fifty percent (50%) of its outstanding
voting shares shall in any event be deemed to confer control, it being understood that the direct or indirect ownership of a lesser percentage of such shares shall not necessarily preclude the existence of control. 

  

	1.3	 	“Agreement” shall mean this document and any annex, addendum, exhibit, attachment, schedule or modification hereto. 

  
 Confidential 

	1.4	 	“Aventis Know-how” means all Information that is (a) owned or Controlled by Aventis at any time during the Term of this Agreement and (b) useful or necessary in the
Field. 

  

	1.5	 	“Control” or “Controlled” when used in connection with intellectual property rights, means that the Party owns or has a license to such
intellectual property rights and has legal authority, right and ability to grant to the other Party access, a license, or a sublicense to such intellectual property rights or to otherwise disclose proprietary or trade secret information to such
other Party, as provided for in this Agreement, without violating any agreement with or the rights of a third party. 

  

	1.6	 	“FDA” means the United States Food and Drug Administration or any successor entity thereto. 

  

	1.7	 	“Field” means the development, manufacture, use and sale of the Products that are or could be developed and sold under this Agreement. 

  

	1.8	 	“First Commercial Sale” means, with respect to any Product, the first sale for end use or consumption of such Product in the United States after all applicable
required Regulatory Approvals have been granted in the United States. 

  

	1.9	 	“GMP” means Good Manufacturing Practices as promulgated under the Act at 21 CFR (chapters 210, 211, 600 and 610), as the same may be amended or re-enacted from time
to time. 

  

	1.10	 	“Improvement” means any enhancement of or improvement to Product and/or its use or indication, whether or not patentable, developed by or for, invented or acquired
by, or coming under the Control of, PharmaNetics during the term of this Agreement. 

  

	1.11	 	“Information” means (i) techniques and data relating to the Field, including, but not limited to, ideas (including patentable inventions), inventions, practices,
methods, knowledge, know-how, trade secrets, skill, experience, documents, apparatus, clinical and regulatory strategies, test data, including pharmacological, toxicological and clinical test data, analytical and quality control data, manufacturing,
patent and legal data or descriptions and (ii) devices, algorithms, chemical formulations, compositions of matter, product samples and assays relating to the Field. 

  

	1.12	 	“Lovenox®” means both the Lovenox® and Clexane®
(enoxaparin sodium) Injection brand prescription pharmaceutical product for which Aventis Pharmaceuticals Products Inc. (then known as Rhone-Poulenc Rorer Pharmaceuticals Inc.) filed an NDA on July 26, 1991 which was re-filed on

  
 Confidential 
  

 Page 2 

	    	 	December 30, 1991 and received FDA approval on March 29, 1993. 

  

	1.13	 	“NDA” means the new drug applications related to Product, submitted to the FDA under Sections 505, 507 or 512 of the Act and applicable regulations related thereto.

  

	1.14	 	“PharmaNetics Know-how” means all Information that is (a) owned or Controlled by PharmaNetics at any time during the Term of this Agreement and (b) useful or
necessary in the Field. PharmaNetics Know-how does not include PharmaNetics Patents. 

  

	1.15	 	“PharmaNetics Patent(s)” means all U.S. patents and patent applications, including all additions, divisions, continuations, continuations-in-part, substitutions,
extensions, patent term extensions and renewals, and patents issued thereon generally directed to one or more aspects of Product that are or become owned or Controlled by PharmaNetics prior to or during the term of this Agreement.

  

	1.16	 	“Product” means an enoxaparin test card and test card system that are approved and labeled exclusively for use with Lovenox®. 

  

	1.17	 	“Regulatory Approval” means (a) in the United States, approval by the FDA of all authorizations, licenses or permits required and satisfaction of any related
applicable FDA registration and notification requirements (if any) and (b) in any country other than the United States, approval by regulatory authorities having jurisdiction over such country of a single application or set of applications filed by
PharmaNetics for approval of all authorizations, licenses or permits required and satisfaction of any related applicable regulatory and notification requirements, if any, together with any other approval necessary to make and sell commercially the
Product in such country, including, where applicable, satisfactory labeling and pricing approval. 

  

	1.18	 	“Term of this Agreement” means the period of time during which this Agreement is in effect under Article 11. 

  

	1.19	 	“Territory” means all the countries in the world. 

  
 Confidential 
  

 Page 3 

 ARTICLE 2 
  

DEVELOPMENT 
  

	2.1	 	Joint Development Committee. 

  

	 	2.1.1	 	Organization. On the Effective Date, the Parties shall organize a Joint Development Committee (“JDC”) consisting of three members from each Party. Each Party will
elect one of its three members to serve as a co-chairperson. The JDC shall be dissolved as soon as practicable after First Commercial Sale of Product in the United States. 

  

	 	2.1.2	 	Function. The function of the JDC shall be to plan, coordinate and manage the clinical development of Product until the First Commercial Sale of Product and to serve as a
forum for communication between the Parties. Each co-chairperson of the JDC will be responsible for keeping the Party he or she represents informed of the status of the development activities. The JDC is not intended to replace any internal
management procedures of either Party. 

  

	 	2.1.3	 	Decision Making. The JDC will operate by consensus, with the representatives of each party having one vote in total, except as set forth in Section 2.1.5.

  

	 	2.1.4	 	Governing Rules. The rules governing the JDC shall include the following: 

  

	 	(a)	 	The timing, agenda and minutes of each JDC meeting will be the responsibility of the co-chairperson hosting the meeting. 

  

	 	(b)	 	The location of the JDC meeting will alternate between PharmaNetics’ facility and one of Aventis’ facilities. 

  

	 	(c)	 	The JDC will meet no less than four times annually. 

  

	 	(d)	 	Non-members of the JDC are welcome to participate provided prior notice is given. 

  

	 	(e)	 	Minutes of each JDC meeting will be summarized within two weeks after the meeting and will not be official until the non-drafting co-chairperson has agreed to them.

  

	 	(f)	 	Each Party will bear its own travel and lodging expenses associated with the JDC and its meetings. 

  

	 	(g)	 	JDC members reporting to a Party may be changed from time to time at the sole discretion of the Party with notice to the other Party. 

  
 Confidential 
  

 Page 4 

	 	2.1.5	 	Dispute Resolution. If the JDC fails to reach consensus on any matter within its jurisdiction, the parties shall refer the matter to the Chief Executive Officer of
PharmaNetics and to a Senior Executive Officer of Aventis. If the executive officers can not reach a decision on any material matter, including but not limited to the design of registration enabling trials, within five (5) business days of the
matter being referred to them, then either Party shall have the right to provide notice of termination of this Agreement to be effective sixty (60) days from the date of the end of such period. If and only if PharmaNetics terminates this Agreement
pursuant to the terms of this Section 2.1.5 and such termination is subsequent to completion of registration enabling trials for the Product designed for the purpose of obtaining Regulatory Approval in the United States, PharmaNetics shall be
subject to a term of non-completion in accordance with Section 11.4. If and only if Aventis terminates this Agreement pursuant to the terms of this Section 2.1.5 and such termination is subsequent to completion of registration enabling trials for
Product designed for the purpose of obtaining Regulatory Approval in the United States, Aventis shall be subject to a term of non-competition in accordance with Section 11.4 

  

	2.2	 	Development Studies. 

  

	 	2.2.1	 	PharmaNetics shall be responsible for, and shall use reasonable efforts to conduct, all work and perform all studies necessary for, obtaining Regulatory Approval for the Products.
Notwithstanding the foregoing, Aventis shall provide reasonable assistance to PharmaNetics with respect to any issues or questions relating to Lovenox® and use reasonable efforts to provide access to those clinical trial sites and related data required to collect the information necessary to
obtain regulatory approval for the Product. 

  

	 	2.2.2	 	Aventis hereby grants to PharmaNetics a limited, nonexclusive, worldwide license to Aventis Know-how in the Field for the sole purpose of conducting studies for the development of
Product. 

  

	 	2.2.3	 	PharmaNetics shall record, to the extent practicable, all Information relating to the development of Product, in standard laboratory notebooks, which shall be signed, dated and
witnessed. To the extent practicable, such notebooks shall be kept separately from notebooks documenting other development activities of PharmaNetics. PharmaNetics shall require its employees and consultants to disclose any inventions relating to
the Product in writing promptly after conception. 

  

	2.3	 	Manufacturing. 

  

	 	2.3.1	 	PharmaNetics shall be responsible for manufacturing testing, release and supply of all Product at its sole cost and expense. The Product will be manufactured and tested in
accordance with GMPs, and all other laws, 

  
 Confidential 
  

 Page 5 

	 	    	 	guidelines and regulations applicable to the manufacture of Product within the Territory and the terms and requirements set forth in this Agreement. 

  

	 	2.3.2	 	The Product will be provided free of charge to Aventis by PharmaNetics as requested by Aventis for use in those development studies being conducted to provide the information
required to obtain regulatory approval of the Product. Should Aventis request Product for use in additional developmental studies, then PharmaNetics will provide the Product at the prices specified in Exhibit A. 

  

	2.4	 	Inspection and Regulatory Compliance. 

  

	 	2.4.1	 	During regular business hours and upon reasonable notice, Aventis personnel shall be permitted to inspect the facilities of PharmaNetics to observe manufacturing activities and
review Product relevant documentation including complaint history and on time delivery performance, for the extent necessary for assessing compliance with applicable regulatory, environmental and other governmental regulations and identifying safety
and occupational risks (if any) associated with the manufacturing activities. 

  

	 	2.4.2	 	PharmaNetics will inform Aventis of the outcome of all regulatory compliance inspections or regulatory action that impact the Product within two (2) business days. PharmaNetics will
make copies of all pertinent inspection reports, regulatory action letters and corrective action submissions available to Aventis within one week of receipt/submission. 

  

	 	2.4.3	 	PharmaNetics will inform Aventis of all recalls regarding the Product within forty-eight (48) hours of recall commencement. 

  
 ARTICLE 3 
  
 REGULATORY AND LABELING 
  

	3.1	 	Regulatory Filings. PharmaNetics shall be responsible for the preparation of suitable applications for Regulatory Approval in the Territory and shall be the owner and party
of record of all such applications.  

  

	3.2	 	Ownership of the Data and Regulatory Approvals. PharmaNetics will be the sole owner of (a) all the data generated by the testing of the Product, (b) the database for such
data, and (c) all Regulatory Approval submissions filed for clinical studies of the Product and any comparable regulatory filings outside the United States. 

  
 Confidential 
  

 Page 6 

	3.3	 	Review of Materials. PharmaNetics shall provide Aventis with drafts of any documents or other correspondence to be submitted to the FDA or such similar regulatory authority
outside of the United States, as well as all communications with investigators, including but not limited to all protocols and presentations to investigators. Aventis shall have ten (10) business days to review and comment on such materials before
submission or other communication may be made. PharmaNetics will use reasonable efforts to accommodate Aventis’ comments prior to submission, presentation or publication of the materials. 

  

	3.4	 	Labeling. 

  

	 	3.4.1	 	The labeling for the Product will be such that the only approved drug or pharmaceutical product with which the Product is approved for usage is Lovenox®. 

  

	 	3.4.2	 	PharmaNetics shall be responsible for all costs associated with labeling the Products; provided, however, that should Aventis have any special requirements with respect to labeling,
then Aventis will be responsible for any excess charges over and above PharmaNetics’ standard costs . 

  

	 	3.4.3	 	Aventis shall supply PharmaNetics with all camera ready artwork and trademarks of Aventis to be applied to the Product and the labels. 

  

	 	3.4.4	 	Aventis shall have 15 days to review and comment on all labeling of Product and any submissions to the FDA or applicable regulatory authority with respect to such labeling, and
PharmaNetics will use reasonable efforts to accommodate Aventis’ comments prior to submission 

  
 ARTICLE 4 
  
 COMMERCIALIZATION 
  

	4.1	 	Joint Commercialization Committee. Not later than the commencement of the registration enabling trials for the Product, the Parties shall organize a Joint Commercialization
Committee (“JCC”) consisting of three members from each Party. Each Party will elect one of its three members to serve as a co-chairperson. 

  

	 	4.1.1	 	Function. The function of the JCC shall be to establish the overall strategy and oversee the commercialization of Product in the Territory. The JCC will have the opportunity
to review and advise the Parties on, with respect to the Product, all market research plans and research results and similar items, as well as PharmaNetics’ proposed marketing and sales budget for Product, for the purpose of advising and
assisting in establishing a U.S. commercialization strategy in the Territory. The JCC is not intended to replace any internal management procedures of either Party. The JCC 

  
 Confidential 
  

 Page 7 

 shall be organized hereunder for consultative purposes only and shall have no decision-making authority
binding on either Party. 
  

	 	4.1.2	 	Decision Making. The objective of the JCC shall be to reach agreement by consensus on all matters falling within its authority hereunder, including, but not limited to the
design, claims and content of promotional materials and the timing of launch of the Product with the Territory. The representatives of each party shall have one vote in total on the JCC. 

  

	 	4.1.3	 	Exception to Joint Decision Making. Except with respect to registration enabling trials, which shall be governed by the principles set forth in Article 2, Aventis, in its
sole discretion, shall have the option to incorporate the Product into any of its ongoing clinical studies involving Lovenox®. PharmaNetics shall provide reasonable assistance to Aventis with respect to any issues of questions related to the Product. Aventis agrees to make the
results of such clinical studies, to the extent that such results relate to the Product, available to PharmaNetics. Neither Party shall initiate, conduct, or enable a third party to conduct clinical studies for the development of the Product except
pursuant to this Agreement. 

  

	4.2	 	Dispute Resolution. 

  

	 	4.2.1	 	Referral of Unsolved Matters to Executive Officers. In the event of a deadlock on the JCC, then the Parties shall refer the matter to the Chief Executive Officer of
PharmaNetics and to a Senior Executive Officer of Aventis to be resolved by negotiation in good faith as soon as is practicable but in no event later than five (5) business days after referral. Such resolution, if any, of a referred issue by the
executive officers shall be final and binding on the parties. If resolution of the deadlock is not achieved within such five (5) day period, then this Agreement shall automatically terminate at the end of sixty (60) days from such date; provided,
however, the parties shall be entitled to continue to attempt to resolve the deadlock during such period, in which case the parties may mutually terminate the automatic sixty (60) day termination. 

  

	 	4.2.2	 	Independent Experts. Such executive shall have the right to engage the services of any number of independent experts in the field in question (the individuals) so engaged by
each executive officer to be engaged under obligations of confidentiality) to assist the executive officer in making a determination on the unresolved matter, and each executive officer shall be obligated to consider in good faith the analysis and
opinions of any such independent experts engaged by either of them in making a determination. 

  

	4.3	 	Efforts. PharmaNetics will use reasonable efforts to commercialize and sell Product in the Territory. 

  
 Confidential 
  

 Page 8 

	4.4	 	Limitations to Field of Commercialization. Except for those particular patient subgroups approved by the JCC (i.e., patients such as those with obesity and renal impairment
that could potentially span the full range of Lovenox® indications), neither Party will promote the Product in the fields of oncology or venous thromboembolism prophylaxis or treatment. 

  

	4.5	 	Advertising/Marketing/Sales Costs. PharmaNetics and Aventis shall each bear their own advertising, marketing and sales costs associated with Product distribution, promotion
and education.  

  

	4.6	 	Packaging. PharmaNetics shall be responsible for all costs of packaging the Product; provided, however, that any additional costs incurred as the result of any special
packaging request received from Aventis shall be paid by Aventis. 

  

	4.7	 	Advertising and Promotional Materials. 

  

	 	4.7.1	 	PharmaNetics shall be responsible for assuring that all promotional material that it produces relating to Product is in material compliance with applicable law.

  

	 	4.7.2	 	PharmaNetics and Aventis shall be jointly responsible for developing and reviewing all advertising, promotional material, labeling and other literature used on, or in connection
with, Product. 

  

	 	4.7.3	 	PharmaNetics shall provide to Aventis, for use by Aventis’ sales force, advertising and promotional materials and literature used in connection with Product, in quantities
reasonably requested by Aventis, at cost to Aventis. 

  

	 	4.7.4	 	PharmaNetics shall provide adequate training to the applicable Aventis United States Advanced Therapeutics sales force, with the frequency and content to be determined by mutual
agreement of the Parties, to allow for detailing of the Product in a manner consistent with Aventis’ obligations as further set forth herein. Such training shall not be conducted more than semi-annually. Training will take place at a central
location to be mutually agreed on by the Parties, and will be provided by PharmaNetics at no additional cost to Aventis, except that Aventis shall pay for all travel and related expenses for its personnel. 

  

	 	4.7.5	 	Aventis’ United States Advanced Therapeutics sales representatives shall include the Product in promotion of Lovenox® to appropriate physician groups in a manner which is not inconsistent with the
Product’s labeling and is in accordance with applicable law. Such promotion shall include (1) informing such physicians as to the availability of the Product, (2) making available approved informational materials with respect to the Product,
(3) providing contacts whereby customers can obtain additional information.  

  
 Confidential 
  

 Page 9 

	 	4.7.6	 	It shall be the obligation of PharmaNetics to arrange for the provision of the additional information referred to in clause (3) of Section 4.7.5 above primarily utilizing a sales
force knowledgeable in the sale of the Product, and where appropriate, either through the use of educational videos or telephone support.  

  

	 	4.7.7	 	In addition to its obligation to promote the Product as described in Section 4.7.5 herein, Aventis shall provide PharmaNetics (to the extent permissible by applicable law or
regulation), with space on any exhibit designed to promote Lovenox® to appropriate physician groups at professional meetings and medical conventions or at appropriate educational symposia Aventis sponsors or promotes. Each Party shall be responsible for its own travel and related
costs. PharmaNetics shall reimburse Aventis for costs related to the provision of space designed exclusively to promote the Product at meetings, conventions or symposia where such costs are approved in advance by PharmaNetics.

  

	 	4.7.8	 	Aventis shall have no obligation to promote (as such activities are described in Section 4.7.5 herein), and PharmaNetics, no obligation to market and distribute, the Product outside
of the United States unless otherwise determined by the JCC. In the event that the JCC determines that the Product shall be marketed, distributed and promoted in any country outside the United States, the obligations of the Parties with respect to
promotional activities and support shall be consistent with the obligations of the Parties in the United States at a scale appropriate for such country. Marketing, distribution or promotion of the Product in any country outside of the United States
shall not obligate Aventis to pay any milestone payments in addition to those set forth in Section 5.1, nor shall such marketing, distribution or promotion have any effect on the timing of such milestone payments.  

 

	4.8	 	Customer Contact. In addition to any advertising and promotional materials PharmaNetics supplies with the Product, PharmaNetics shall, prior to First Commercial Sale: (1)
create and host an informational website, or a portion of an already existing website, dedicated to the Product; and (2) establish a toll free number whereby consumers can contact PharmaNetics representatives with any questions such consumer may
have regarding Product. 

  

	4.9	 	Provision of Analyzers. The Parties acknowledge that in order to effectively promote and sell the Product, it will be necessary for all relevant customer targets to have
ready access to PharmaNetics’ dry chemistry Thrombolytic Assessment System within which test cards are analyzed. Accordingly, PharmaNetics will use reasonable efforts to make the Thrombolytic Assessment System commercially available to heart
catheterization laboratories in the United States that in the determination of the JCC routinely perform coronary interventions. 

  
 Confidential 
  

 Page 10 

 ARTICLE 5 
  

PAYMENT TERMS 
  

	5.1	 	Milestone Payments. Aventis shall make the following nonrefundable milestone payments to PharmaNetics upon occurrence of the following events: 

  

	 	5.1.1	 	$1,000,000 within 15 days of the execution of this Agreement; 

  

	 	5.1.2	 	$1,000,000 upon completion of registration enabling trials for the Product designed for the purpose of obtaining Regulatory Approval in the United States. 

 

	 	5.1.3	 	$1,500,000 upon issuance by the FDA of a Regulatory Approval for the Product; and 

  

	 	5.1.4	 	$1,500,000 upon First Commercial Sale of Product in the United States. 

  

	5.2	 	Currency of Payment. All payments to be made by Aventis to PharmaNetics hereunder shall be made in U.S. Dollars. 

  
 ARTICLE 6 
  
 EXCLUSIVITY 
  

	6.1	 	Competitors of Lovenox®. From the Effective Date of this Agreement through the fourth anniversary of First Commercial Sale: (1) neither PharmaNetics nor Aventis shall develop, have developed, assist in the
development of, market, have marketed, assist in the marketing of, manufacture, have manufactured or assist in the manufacture of a Low Molecular Weight Heparin (“LMWH”) test card or system for Lovenox®, other than in furtherance of this Agreement, or for any LMWH drug which competes with
Lovenox® in the Territory; and (2) in furtherance
of this objective, the Parties agree, for as long as this Agreement is effective, that, in no communications with third parties, whether orally or in writing, will the Product be referred to as a “LMWH Test Card” but instead as an
Enoxaparin or Lovenox® Test Card.

  

	6.2	 	Enabling of Product. From and after the Effective Date, neither PharmaNetics nor Aventis shall knowingly enable any third party to use the Product for any drug or
pharmaceutical product other than Lovenox®.

  
 Confidential 
  

 Page 11 

 ARTICLE 7 
  

INTELLECTUAL PROPERTY 
  

	7.1	 	Trademarks. 

  

	 	7.1.1	 	Each Party acknowledges that any and all trademarks and service marks (the “Marks”) of the other Party are, and shall remain, the sole property of the other Party.

  

	 	7.1.2	 	Except as expressly stated herein, no license of, or ownership interests in, either Party’s Marks to the other Party is created pursuant to this Agreement. Such use shall be in
accordance with good intellectual property practices including, but not limited to, protecting the value of the good will residing in such Marks. 

  

	 	7.1.3	 	Neither Party shall use the other Party’s Marks in a manner that disparages such other Party or its products or services, or portrays the other Party or its products or
services in a false, competitively adverse or negative light. 

  

	7.2	 	Patents. PharmaNetics shall take all reasonable steps to maintain for the full life thereof all issued Patents, owned or Controlled by PharmaNetics, which underlie the
Products. 

  

	7.3	 	Improvements. Each Party acknowledges that Improvements shall be the sole property of PharmaNetics. Aventis agrees to take any and all action reasonably required by
PharmaNetics, including execution of assignments or other documentation, to perfect PharmaNetics’ rights in and to such Improvements. 

  

	7.4	 	Infringement of Third Party Rights. 

  

	 	7.4.1	 	Costs of Defense. PharmaNetics shall be responsible for the reasonable fees and costs of attorneys and consultants, together with the court costs, incurred by both Parties in
defending against claims by third parties that the Product violates any third party intellectual property right (a “Product Claim”). Aventis shall be responsible for the reasonable fees and costs of attorneys and consultants, together with
the court costs, incurred by both Parties in defending against any claims that Lovenox® violates any third party intellectual property rights (a “Lovenox® Claim”). 

  

	 	7.4.2	 	Payments to Third Parties. If either Party is required by a final court order or a settlement agreement entered into in good faith to make royalty payments or other payments
to a third party in connection with the disposition of any Product Claim, PharmaNetics shall make or reimburse to Aventis all such payments. If either Party is required by a final court order or a settlement agreement entered into in good faith to
make royalty 

  
 Confidential 
  

 Page 12 

 payments or other payments to a third party in connection with the disposition of any Lovenox® Claim, Aventis shall make or reimburse to PharmaNetics
all such payments. 
  

	 	7.4.3	 	No Third Party Effect. Neither this Article 7, nor any exercise of rights or fulfillment of obligations under this Article 7, shall affect by itself any indemnification or
contribution rights of either Party against any third party. 

  

	7.5	 	Infringement by Third Parties. 

  

	 	7.5.1	 	Notice. If any of the PharmaNetics Patent Rights or PharmaNetics Know-how in the Field is infringed by a third party, the Party first having knowledge of such infringement
shall promptly notify the other in writing. The notice shall set forth the facts of such infringement in reasonable detail. 

  

	 	7.5.2	 	Prosecution of Actions Related to Product. 

  

	 	(a)	 	PharmaNetics shall have the primary right to institute, prosecute and control any action or proceeding with respect to any infringement of Product, by counsel of its own choice and
reasonably acceptable to Aventis. Aventis shall cooperate at PharmaNetics’ cost with PharmaNetics at PharmaNetics’ reasonable request in the prosecution of such action or proceeding. 

  

	 	(b)	 	If PharmaNetics fails to bring an action or proceeding within a period of thirty (30) days after receiving written notice from Aventis or otherwise having knowledge of that
infringement, Aventis shall have the right to bring and control any such action by counsel of its own choice and expense. 

  

	 	(c)	 	No settlement, consent judgment or other voluntary final disposition of a suit under this Article 7 may be entered into without the joint consent of Aventis and PharmaNetics (which
consent shall not be withheld unreasonably). 

  

	 	(d)	 	If PharmaNetics brings such an action, PharmaNetics shall retain any damages or other monetary awards recovered by PharmaNetics. 

  

	 	(e)	 	If PharmaNetics fails to bring such an action and Aventis brings action, any damages or other monetary awards recovered by Aventis shall be retained by Aventis.

  
 Confidential 
  

 Page 13 

 ARTICLE 8 
  

REPRESENTATIONS AND WARRANTIES 
  

	8.1	 	Representations by PharmaNetics. PharmaNetics hereby represents and warrants to Aventis as follows: 

  

	 	8.1.1	 	The Product (a) shall be manufactured and packaged in compliance with current GMPs, as established and revised from time to time by the FDA, applicable Regulatory Approval
applications, and all other U.S. and other governmental rules and regulations applicable to the Product and its manufacture, (b) shall conform to the specifications for the Product in effect at the time of delivery, (c) shall not be adulterated or
misbranded within the meaning of the Act, nor constitute an article that may not be introduced into interstate commerce under the provisions of Section 505 of the Act, (d) shall conform to the certificates of analysis supplied with the shipment of
the Product, (e) shall be packaged and shipped in accordance with mutually agreed to procedures, and (f) shall be free and clear of any lien or encumbrance; 

  

	 	8.1.2	 	PharmaNetics has delivered to Aventis copies of all PharmaNetics Know-how, together with any other information now owned or controlled by PharmaNetics that PharmaNetics believes is
reasonably necessary or useful to a complete understanding of the prospects for the Product, including without limitation complete reports on all serious adverse experiences associated with the use of Product with any pharmaceutical product or other
substance; 

  

	 	8.1.3	 	All PharmaNetics Know-how and other Information of a material nature delivered by PharmaNetics to Aventis was accurate, correct and complete; 

  

	 	8.1.4	 	PharmaNetics has sufficient legal and/or beneficial right, title and interest in, to and under the PharmaNetics Patent Rights, the PharmaNetics Know-how and its other intellectual
property rights to perform its obligations under this Agreement; 

  

	 	8.1.5	 	The conduct of its business as proposed under this Agreement would not to the knowledge of PharmaNetics violate any of the intellectual property rights of any other person or entity
relating to the Products; 

  

	 	8.1.6	 	PharmaNetics believes that there is no material unauthorized use, infringement or misappropriation of any PharmaNetics Know-how or PharmaNetics Patent Rights;

  

	 	8.1.7	 	PharmaNetics’ execution and delivery of this Agreement and its performance of its obligations under this Agreement will not violate any 

  
 Confidential 
  

 Page 14 

 federal, state, municipal statute or regulation or any order of any court or other governmental
department, authority, agency or instrumentality; 
  

	 	8.1.8	 	All of PharmaNetics’ employees, officers, relevant subcontractors and relevant consultants have executed agreements requiring assignment to it of all inventions made during the
course of and as a result of their association with it and obligating the individual to maintain as confidential the confidential information of it, as well as the confidential information of a third party which it may receive;

  

	 	8.1.9	 	PharmaNetics has not, and during the Term of this Agreement will not, grant any right to any third party relating to PharmaNetics Patents and PharmaNetics Know-how which would
conflict with the rights granted to Aventis hereunder; and 

  

	 	8.1.10	 	During the Term of this Agreement, PharmaNetics will not knowingly infringe any valid third party intellectual property rights related to the Product in its conduct of any activity
under the Project. 

  

	8.2	 	Representations and Warranties of Aventis. Aventis hereby represents and warrants to PharmaNetics as follows: 

  

	 	8.2.1	 	Aventis’ execution and delivery of this Agreement and its performance of its obligations under this Agreement will not violate any federal, state, municipal statute or
regulation or any order of any court or other governmental department, authority, agency or instrumentality; 

  

	 	8.2.2	 	Aventis has delivered to PharmaNetics copies of all Aventis Know-how, together with any other information now owned or controlled by Aventis that Aventis believes is reasonably
necessary or useful to a complete understanding of the prospects for developing the Product to support Lovenox®; 

  

	 	8.2.3	 	All Aventis Know-how and other Information of a material nature delivered by Aventis to PharmaNetics was accurate and correct; 

  

	 	8.2.4	 	Aventis has not, and during the Term of this Agreement will not, grant any right to any third party relating to Aventis Know-how in the Field which would conflict with the rights
granted to PharmaNetics hereunder; and 

  

	 	8.2.5	 	Aventis will not knowingly infringe any valid third party intellectual property rights related to Product in its conduct of any activity under the Project. 

 

	8.3	 	Disclaimer of Warranties. EXCEPT FOR THE WARRANTIES CONTAINED IN THIS SECTION 8, THE PARTIES HEREBY DISCLAIM ANY AND ALL OTHER WARRANTIES, EXPRESS, IMPLIED OR STATUTORY
INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY OF CONDITION, PERFORMANCE, 

  
 Confidential 
  

 Page 15 

 SATISFACTORY QUALITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE. 
  
 ARTICLE 9 
  
 INDEMNIFICATION AND INSURANCE 
  

	9.1	 	Employees. Each Party shall indemnify the other Party, such other Party’s successors and assigns, and the directors, officers, employees, agents and counsel thereof (the
“Other Party’s Indemnitees”), defend and hold each Other Party’s Indemnitee harmless from and against, on an after-tax basis, any and all liabilities, damages, settlements, claims, actions, suits, penalties, fines, costs or
expenses (including without limitation reasonable attorneys’ fees) (any of the foregoing being referred to collectively as “Damages”) incurred by or asserted against any Other Party’s Indemnitee by or on behalf of the
indemnifying Party’s employees that arise out of a breach of this Agreement by such employees. 

  

	9.2	 	Aventis’ Right to Indemnification. PharmaNetics shall indemnify each of Aventis, its successors and assigns, and the directors, officers, employees, agents and counsel
thereof (the “Aventis Indemnitees”), defend and hold each Aventis Indemnitee harmless from and against, on an after-tax basis, any and all Damages incurred by or asserted against any Aventis Indemnitee of whatever kind or nature,
including, without limitation, any claim or liability based upon negligence, warranty, strict liability, violation of government regulation or infringement of patent or other proprietary rights, but only to the extent arising from or occurring as a
result of a third party claim against any Aventis Indemnitee because of (a) breach of any warranty made by PharmaNetics in Section 8; (b) the failure of PharmaNetics to manufacture, process, test or package Product according to specifications and
the sale or promotion of any Product by or on behalf of PharmaNetics (except activities undertaken by Aventis); (c) the failure of PharmaNetics to disclose any material or drug safety information in PharmaNetics’ possession to Aventis regarding
any Product; (d) the labeling, warehousing, distribution or detailing of a Product by PharmaNetics that is not in conformity with representation and warranties made under this agreement by PharmaNetics; (e) any breach of this Agreement by
PharmaNetics, or (f) any product liability claim resulting in a judgment against, as a negotiated settlement entered into by, PharmaNetics relating to the Product, except, in each such case, to the extent that such Damages result from the negligence
or misconduct of Aventis or its licensees (except activities undertaken by PharmaNetics), or the breach by Aventis of any obligation or warranty under this Agreement, or any claims compromised or settled without PharmaNetics’ prior written
consent. Aventis shall promptly notify PharmaNetics of any third party claim, upon becoming aware thereof, and permit PharmaNetics at PharmaNetics’ cost to defend Aventis against such third party claim and to control the defense and disposition
(including, without limitation, all decisions to litigate, settle or appeal) of such third party claim and shall cooperate in the defense thereof. Aventis may, at its option and expense, have its own counsel participate in any proceeding that is
under the direction of PharmaNetics and will cooperate with PharmaNetics and its insurer in the disposition of any such matter. PharmaNetics shall not be liable for 

  
 Confidential 
  

 Page 16 

 any litigation costs or expenses incurred by the Aventis Indemnitees without PharmaNetics’ prior
written authorization. 
  

	9.3	 	PharmaNetics’ Right to Indemnification. Aventis shall indemnify each of PharmaNetics, its successors and assigns, and the directors, officers, employees, agents and
counsel thereof (the “PharmaNetics Indemnitees”), defend and hold each PharmaNetics Indemnitee harmless from and against, on an after-tax basis, any and all Damages incurred by or asserted against any PharmaNetics Indemnitee of whatever
kind or nature, including, without limitation, any claim or liability based upon negligence, warranty, strict liability, violation of government regulation or infringement of patent or other proprietary rights, but only to the extent arising from or
occurring as a result of a third party claim against any PharmaNetics Indemnitee because of (a) breach of any warranty made by Aventis in Section 8; (b) any breach of this Agreement by Aventis, except, in each such case, to the extent that such
Damages result from the negligence or misconduct of PharmaNetics or its licensees (except activities undertaken by Aventis), or the breach by PharmaNetics of any obligation or warranty under this Agreement, or any claims compromised or settled
without Aventis’ prior written consent. PharmaNetics shall promptly notify Aventis of any third party claim, upon becoming aware thereof, and permit Aventis at Aventis’ cost to defend PharmaNetics against such third party claim and to
control the defense and disposition (including, without limitation, all decisions to litigate, settle or appeal) of such third party claim and shall cooperate in the defense thereof. PharmaNetics may, at its option and expense, have its own counsel
participate in any proceeding that is under the direction of Aventis and will cooperate with Aventis and its insurer in the disposition of any such matter. Aventis shall not be liable for any litigation costs or expenses incurred by the PharmaNetics
Indemnitees without Aventis’ prior written authorization. 

  

	9.4	 	Insurance. PharmaNetics represents and warrants to Aventis that it has sufficient insurance to adequately protect PharmaNetics and Aventis (a) from any and all claims by
employees of PharmaNetics for bodily injury (including death), whether or not such claims are under applicable worker’s compensation act; and (b) from any and all claims for injury (including death), loss or damage to any person or property
which may arise or result from any allegedly tortious act, omission or statement of PharmaNetics or any person employed by or under contract with PharmaNetics. PharmaNetics shall require subcontractors, if any, to carry worker’s compensation
insurance and adequate liability insurance. These insurance provisions in no way alter either party’s indemnification obligations as set forth in this Agreement. In no event shall the type, form and amount of insurance coverage maintained by
PharmaNetics be less than the following minimum amounts: 

  
 Confidential 
  

 Page 17 

	 Type

	 	 Amount

	 Worker’s Compensation Ins.
	 	As required by law
		
	 Employer’s Liability
	 	$  1,000,000
		
	 Comprehensive General Liability (CLS)
	 	$     500,000
		
	 Third Party Liability Bodily Injury / Property Damage (includes Independent Contractor Coverage, Completed Operations or Product
Coverage, Blanket Contractual, Explosion, Collapse, underground, Broad Form Property Damage, 30-Day Notice of Cancellation, Aventis as an Additional Insured)
	 	 $  1,000,000

		
	 Automobile Liability (CLS) Bodily Injury
	 	$  1,000,000
		
	 Umbrella Liability Coverage(with Aventis named as an additional insured)
	 	$14,000,000

  
 Aventis represents
and warrants to PharmaNetics that it is adequately insured to protect PharmaNetics and Aventis against Aventis’ liabilities and risks under this Agreement. 
  

ARTICLE 10 
  
 CONFIDENTIALITY 
  

	10.1	 	Confidentiality of Disclosed Information. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, for the Term of
this Agreement and for ten (10) years thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any Information or other information
furnished to it by the other Party pursuant to this Agreement (collectively, “Confidential Information”). 

  

	10.2	 	Exceptions. Confidential Information shall not include information that: 

  

	 	(a)	 	Was already known by the receiving Party, other than under an obligation of confidentiality, at the time of disclosure to the receiving Party; 

  
 Confidential 
  

 Page 18 

	 	(b)	 	Was generally available to the public or otherwise part of the public domain at the time of disclosure to the receiving Party; 

  

	 	(c)	 	Became generally available to the public or otherwise part of the public domain after the time of disclosure to the receiving Party other than through any act or omission of the
receiving Party in breach of this Agreement; or 

  

	 	(d)	 	Was disclosed to the receiving Party, other than under an obligation of confidentiality, by a third party not obligated to the disclosing Party not to disclose such Information to
others. 

  
 In addition, the provisions of this
Section 10 shall not preclude the receiving Party from disclosing Confidential Information to the extent such Confidential Information is required to be disclosed by the receiving Party or its Affiliates to comply with applicable laws, to defend or
prosecute litigation or to comply with governmental regulations, provided that the receiving Party provides prior written notice of such disclosure to the disclosing Party and takes reasonable and lawful actions to avoid and/or minimize the degree
of such disclosure. Specific information shall not be deemed to be within any of the foregoing exclusions merely because it is embraced by more general information falling within these exclusions. 
  

	10.3	 	Employee and Advisor Obligations. PharmaNetics and Aventis each agree that they shall provide Confidential Information received from the other Party only to their respective
employees, consultants and advisors who have a need to know and have an obligation to treat such information and materials as confidential. 

  
 ARTICLE 11 
  
 TERM AND TERMINATION 
  

	11.1	 	Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated in whole or in part as specifically provided in the Agreement, shall continue in
effect for perpetuity. 

  

	11.2	 	Termination for Default. If either Party is in default of any of its material obligations under this Agreement and (1) fails to remedy that default within 30 days after
receipt of written notice of such default or (2) the default is the second such default in 12 months, the Party not in default may terminate this Agreement immediately by giving written notice of such termination. A termination of or material change
to a Regulatory Approval for the Product shall constitute an event of default. 

  

	11.3	 	Termination for Bankruptcy. In the event that a Party becomes bankrupt or insolvent, a receiver or a trustee is appointed for the property or estate of such

  
 Confidential 
  

 Page 19 

 Party and said receiver or trustee is not removed within 60 days, or such Party makes an assignment for
the benefit of its creditors, and whether any of the aforesaid events be the outcome of the voluntary act of that Party, or otherwise, the other Party shall be entitled to terminate this Agreement forthwith by giving written notice to such Party.

  

	11.4	 	Early Termination for Failure to Resolve Dispute: Non-Compete. Either Party shall have the right to terminate this Agreement in accordance with the provisions of Section
2.1.5 and Section 4.2.4. In the Event of such termination, and subject to the provisions and limitations of Section 2.1.5 and Section 4.2.4, (A) PharmaNetics agrees that, other than the sale of the Products, neither it nor any of its Affiliates
shall, by license or otherwise, manufacture, market, sell, detail, promote or distribute a Low Molecular Weight Heparin test, and/or a system for any Low Molecular Weight Heparin drug that competes with Lovenox; and (B) Aventis agrees that neither
it nor any of its subsidiaries shall, by license or otherwise, manufacture, market, sell, detail, promote or distribute a Low Molecular Weight Heparin test and/or system. The time period for which such obligations apply shall be as follows:

  

	 	(a)	 	If such termination right is exercised prior to the payment of the milestone for completion of registration enabling trials set forth in Section 5.1.2, then for three (3) years from
First Commercial Sale of Product; provided, however, if such termination right is exercised by Aventis, then there shall be no restrictions on PharmaNetics. 

  

	 	(b)	 	If such termination right is exercised within two years of payment of the milestone for completion of registration enabling trials set forth in Section 5.1.2, then for three (3)
years from the effective date of such early termination; 

  

	 	(c)	 	If such termination right is exercised between the second and third anniversary of payment of the milestone for completion of registration enabling trials set forth in Section
5.1.2, then for two (2) years from the effective date of such early termination; or 

  

	 	(d)	 	If such termination right is exercised between the third and fourth anniversary of payment of the milestone for completion of registration enabling trials set forth in Section
5.1.2, then for one (1) year from the effective date of such early termination. 

  

	11.5	 	Surviving Rights. The obligations of the Parties under Articles 9 and 10 and Sections 3.2, 7.3 and 8.3, 11.4 and 11.7 will survive the termination or expiration of this
Agreement. 

  

	11.6	 	Accrued Rights; Surviving Obligations. Termination, relinquishment or expiration of the Agreement for any reason shall be without prejudice to any rights that shall

  
 Confidential 
  

 Page 20 

 have accrued to the benefit of either Party prior to such termination, relinquishment or expiration. Such
termination, relinquishment or expiration shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of the Agreement. 
  

	11.7	 	Record Keeping and Audits. 

  

	 	11.7.1	 	PharmaNetics. PharmaNetics shall keep complete and accurate records pertaining to the development, use and sale of Product in sufficient detail to permit Aventis to confirm
PharmaNetics’ research and development efforts, its manufacturing and processing activities, its clinical research, and regulatory approval and commercialization efforts. Such records shall be maintained for the longer of: a) four (4) years
following the year in which any such efforts were made hereunder and b) such longer period as may be required by law. 

  

	 	11.7.2	 	Aventis. Aventis shall keep complete and accurate records pertaining to its promotion of the Product in sufficient detail to permit PharmaNetics to confirm Aventis’
efforts to actively promote the Product as described in Section 4.5.5 herein. Such records shall include all information collected by Aventis relating to the Product, including but not limited to information documenting (1) the training of
Aventis’ Advanced Therapeutics sales force on the operation and promotion of the device and (2) the adequate provision of promotional materials to the Aventis sales force necessary for the promotion of the Product. Such records shall be
maintained for the longer of: (a) 4 years following the year in which any such efforts were made hereunder and (b) such longer period as may be required by law. 

  

	 	11.7.3	 	Audit Requests. Each Party shall have the right to audit the records maintained by the other Party to comply with this Section 11.7, at its own expense and on an annual
basis, to determine, with respect to any calendar year, the correctness of any report made, or the performance of such other Party’s obligations, under this Agreement, but only once with respect to each calendar year. If a Party desires to
audit the other Party’s records, it shall do so itself or engage an independent, certified public accountant reasonably acceptable to the other Party, to examine such records. Any Information received by a Party pursuant to this Section 11.7
shall be deemed to be Confidential Information. This Section 11.7 shall survive any termination of this Agreement for a period of four (4) years. 

  

ARTICLE 12 
  
 GENERAL 
  

	12.1	 	Agency. Neither Party is, nor shall be deemed to be, an employee, agent, co-venturer or legal representative of the other Party for any purpose. Neither Party

  
 Confidential 
  

 Page 21 

 shall be entitled to enter into any contracts in the name of, or on behalf of the other Party, nor shall
either Party be entitled to pledge the credit of the other Party in any way or hold itself out as having the authority to do so. 
  

	12.2	 	Assignment. Except as otherwise provided herein, neither this Agreement nor any interest hereunder shall be assignable by any Party without the prior written consent of the
other; provided, however, that either party may assign this Agreement to an Affiliate in a manner such that the assignor shall remain liable and responsible for the performance and observance of all its duties and obligations hereunder. This
Agreement shall be binding upon the successors and permitted assignees of the Parties and the name of a party appearing herein shall be deemed to include the names of such Party’s successor’s and permitted assigns to the extent necessary
to carry out the intent of this Agreement. Any assignment not in accordance with this Section shall be void. 

  

	12.3	 	Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to
carry out the purposes and intent of the Agreement. 

  

	12.4	 	Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be deemed effectively given and received (a) upon personal
delivery, (b) on the fifth day following mailing by registered or certified mail, return receipt requested, postage prepaid, addressed to the PharmaNetics and Aventis at their respective addresses as listed below (or at such other address for a
Party as shall be specified by like notice; provided, that notices of a change of address shall be effective only upon receipt thereof), (c) upon transmission of telegram or facsimile (with telephonic notice), or (d) upon confirmed delivery by
overnight commercial courier service: 

  

	 If to Aventis, addressed to:
	 	Aventis Pharmaceuticals Products Inc.
	 	 	Global Marketing & Medical
	 	 	 Route 202-206

	 	 	PO Box 6800
	 	 	Bridgewater, NJ 08807
	 	 	Attention: Product Director - Lovenox®
		
	 With copy to:
	 	Vice-President, Legal Corporate Development
		
	 If to PharmaNetics, addressed to:
	 	PharmaNetics
	 	 	5301 Departure Drive
	 	 	 Raleigh, North Carolina 27616

	 	 	Attention: President
		
	 With copy to:
	 	Larry E. Robbins, Esq.
	 	 	Wyrick Robbins Yates & Ponton LLP

  
 Confidential

  

 Page 22 

	 	 	 4101 Lake Boone Trail, Suite 300

	 	 	Raleigh, North Carolina 27607

  

	12.5	 	Amendment; Approval. No amendment, modification or supplement of any provision of the Agreement shall be valid or effective unless made in writing and signed by a duly
authorized officer of each Party. No approval provided for in this Agreement shall be valid or effective unless confirmed in writing. 

  

	12.6	 	Waiver. No provision of the Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly
waiving such provision and signed by a duly authorized officer of the waiving Party. 

  

	12.7	 	Severability. Whenever possible, each provision of the Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of
the Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of the Agreement In the event of such invalidity,
the Parties shall seek to agree on an alternative enforceable provision that preserves the original purpose of this Agreement. 

  

	12.8	 	Entire Agreement of the Parties. This Agreement, including the other written agreements referred to herein and the Exhibits attached hereto, constitutes and contains the
complete, final and exclusive understanding and agreement of the Parties hereto and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the
subject matter hereof. To the extent appropriate, the provisions of this Agreement shall apply to the other agreements referred to herein. 

  

	12.9	 	Counterparts. This Agreement may be executed in two counterparts, each of which shall be deemed an original, but both of which together shall constitute one instrument.

  

	12.10	 	Descriptive Headings. The descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing or interpreting any of the
provisions of this Agreement. 

  

	12.11	 	Governing Law. This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of Delaware, without regard to choice of law rules.

  

	12.12	 	Public Announcements. Neither party shall make any public announcement concerning the transactions contemplated herein, or make any public statement which includes the name
of the other party or any of its Affiliates, or otherwise use the name of the other party or any of its Affiliates in any public statement or 

  
 Confidential 
  

 Page 23 

 document, except as may be required legally by law or judicial order, without the prior written consent
of the other party, which consent shall not be unreasonably withheld. A party proposing a public announcement will provide the other party a copy for comment at least five (5) business days in advance or such lesser period of time if not
practicable. The parties agree that upon execution of this Agreement, that the Parties shall issue a joint press release in the form attached hereto as Exhibit B. 
  

	12.13	 	Third Party Beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by any third party, including, without limitation, any creditor
of either party hereto. No such third party shall obtain any right under any provision of this Agreement or shall by reasons of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against either party
hereto. 

  

	12.14	 	Force Majeure. No party shall be liable for failure of or delay in performing obligations set forth in this Agreement, and no party shall be deemed in breach of its
obligations, if such failure or delay is due to natural disasters or any causes reasonably beyond the control of such party. 

  
 [Remainder of page intentionally left blank] 
  
 Confidential 
  

 Page 24 

 IN WITNESS WHEREOF, the Parties hereto have as of the Effective Date duly executed this Agreement,
including the attached Exhibits that are incorporated herein and made a part hereof. 
  

	 AVENTIS PHARMACEUTICALS PRODUCTS INC.
	 	 	 	 PHARMANETICS, INC.

					
	 By:
	 	 /s/    JOHN R. LEONE

	 	 	 	 By:
	 	 /s/    JOHN FUNKHOUSER

	 Name:
	 	John R. Leone	 	 	 	 Name:
	 	John Funkhouser
	 Title:
	 	 Sr. Vice President & CEO
 U. S. Commercial Operations
	 	 	 	 Title:
	 	President & CEO

  

		
	 By:
	 	 /s/    J. DAVID OWENS

	 Name:
	 	J. David Owens
	 Title:
	 	 Vice President, Global Marketing &
 Medical-Cardiology/Thrombosis

  
 Confidential

  

 Page 25 

 EXHIBIT A 
  

Clinical Test Pricing 
  
 Cost to be negotiated on a trial-by-trial basis, but not to exceed the following 
  

	Enozaparin Test Card	 	Prior to First Commercial Sale	 	$25.00 each
			
	Enozaparin Test Card	 	After First Commercial Sale	 	$12.50 each

  
  
  
 Confidential 
  

 26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}]]